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The incidence of breast cancer is the highest among Singaporean women, with more 
then 1000 new cases diagnosed each year. There is an urgent need for new forms of 
treatment i.e. complementary/ alternative medicine (CAM). Traditional Chinese 
Medicine (TCM) is the most popular type of CAM for the treatment of cancer among 
the Chinese population in Singapore.  In most cases it is used to complement 
conventional treatment (surgery, radio-, chemo- and/or hormonal therapy). 
We sought a scientific evaluation of the medicinal herbs that might have 
immunomodulatory and/or anti-tumor effects and could palliate the side-effects 
(nausea, insomnia, pain and fatigue) of chemo- and radiotherapy.  
The investigation was carried out in two phases. In the clinical phase of our study, a 
quality-of- life (QOL) analysis of completed questionnaires from 6 patients was 
performed using the European Organization for Research and Treatment of Cancer 
(EORTC) QOL questionnaire (QLQ-C30 version 3.0) and the supplementary breast 
cancer module (QLQ-BR23). We compared the herbal prescription of the patients 
who had better scores on the symptoms scale (i.e. less fatigue, pain, dyspnoea, 
insomnia and appetite loss).  
In the laboratory phase, we selected the 2 herbs, Astragalus membranaceus (AM) and 
Curcuma aromatica (CA) that we found to be the most frequently prescribed for their 
possible immunomodulatory effect. We tested these herbs for their effects on 
lymphocyte activation and cytokine (IL-2, IL-6, TNF-α) production. 
We also selected Solanum nigrum (SN) which was used for its cytotoxic property 
against breast cancer. We evaluated the tumor cell growth inhibitory effect of the 
 xvii
crude ethanolic extract of SN on MCF-7, T-47D, ZR-75 and MDA-MB -231 human 
breast cancer cell lines. The lowest ED50=7.75 µg/ml was obtained with the estrogen-
dependent MCF-7 cell line. We also demonstrated apoptosis as the cause of cell 
death, both by ELISA and histopathology. 
Experiments were also conducted in oophorectomized nude mice models with breast 
tumor implants. The anti-tumor activity of SN was assumed in these animals by 
measuring tumor growth and life span prolongation as parameters. We found that SN 
treatment caused irreversible tumor regression where the tumor size was relatively 
small (MCF-7 and MDA-MB-231) or when it was given simultaneously with the 
tumor implant. SN 300 mg/kg BW was effective against small volume tumors but not 
efficient against larger, multiple tumors. SN 500 mg/kg BW could be used as 
prevention (producing a prophylactic rate of 75%) but was not an efficient dose of 
invasive tumors. Mice bearing human breast tumors treated with SN maintained their 
original body weight without any change in behavior. 







































1.1 Traditional Chinese Medicine (TCM) 
 
Complementary and alternative medicine (CAM) is a booming healthcare industry in 
Europe and U.S.A. and is used by 25%-69% of the general population of developed 
countries (Richardson et al., 2000).  
CAM has been defined as “diagnosis, treatment and/or prevention which complements 
mainstream medicine by contributing to a common whole, by satisfying a demand not 
met by orthodoxy or by diversifying the conceptual frameworks of medicine” (Ernst et 
al., 1995).  It has also been described as “medical and healthcare practices outside the 
realm of conventional medicine, which are yet to be validated using scientific methods” 
(National Center for Complementary and Alternative Medicine, Strategic Plan, 2000).  
In South-East Asia, the most frequently used CAM interventions are Traditional 
Chinese Medicine (TCM) and Ayurvedic Medicine systems (Dobs, 2001).  TCM 
includes different treatment modalities such as herbal medicine, acupuncture, 
moxibustion, oriental massage, qi-gong and diet.  The practice of herbal TCM 
(“phytotherapy”) has been defined as “the use of products derived from plants to treat 
diseases or eliminate pain” (The Cochrane Collaboration, 1993).   
In Singapore, acupuncture and herbal TCM are the most popular forms of alternative 
medicine due to the majority of the population being ethnic Chinese (personal 
communication with Dr. Teo Eng Kiat; 2001), principal of the Singapore College of 
TCM and Chairman, TCM Practitioners Board Examination Committee, Singapore.  
Singaporeans of Chinese descent, who comprise 76.8% of the total population 
(Singapore Department of Statistics, 2000), have used TCM for many decades, and tend 
to turn to this form of treatment for a variety of diseases, from simple colds to advanced 
cancer  (Ho et al., 1980).   
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According to Dr. Teo, as many as 40% of the Singapore population seek TCM 
treatment as the primary form of treatment. Statistics compiled in 1994 indicate that an 
estimated 12% of the daily outpatient attendance of about 10,000 people was seen by 
TCM practitioners (Hsu et al.,1995). 
With the recent legislation requiring all TCM practitioners in Singapore to upgrade their 
skills and knowledge to obtain certification to practice by the local health regulatory 
authority, the percentage of TCM users is likely to increase in the coming years (Health 
Science Authorities, Singapore, 2002).  
One important reason for the choice of TCM is economic - it is considered a more 
affordable form of health care, compared to the more sophisticated form of Western 
medicine. Some of the clinics in Singapore, like the Chung Hwa Free Clinic, offer free 
consultation and treatment to cancer sufferers. Some of the patients who seek TCM 
treatment do so because they believe it has less side effects and toxicity, and can 
improve their immune system.  Other patients have incurable end-stage disease (e.g. 
chronic renal failure, liver cirrhosis, cancer), where conventional treatment has failed to 
cure, and TCM is tried as a last choice treatment to relieve their symptoms and prolong 
life (Ernst et al.,, 1998; Richardson et al., 2000). 
Some cancer patients in Singapore do take TCM at some stage of their illness.  Most of 
these patients do not disclose this to their physicians as they fear losing their doctor’s 
trust or being discriminated against.  Thus primary care physicians usually 
underestimate their patients’ use of complementary medicine. In USA, 72% of the 
patients fail to report to their physicians the use of CAM. In Israel, one study showed 
that only 18.7% of CAM-using patients reported having ever used CAM (Eisenberg et 
al., 1993; Kitai et al., 1998; Giveon et al., 2003). A similar problem was reported in 
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Canada, where only 46.4% of breast cancer patients reported their use of CAM to their 
physician (Boon et al., 2000).  
The current approach of physicians to complementary medicine in primary care is 
essentially “don’t ask, don’t tell” (Perlman et al., 1999).  
There is a generally low acceptance of herbal TCM by oncologists and other 
conventional medical practitioners here and elsewhere.  Their main concerns are that 
herbal medicine might be contaminated with high levels of toxic heavy metals, such as 
mercury or lead (Wong et al., 1985) and could cause direct adverse effects such as 
allergic reactions, nausea, vomiting and sedation (Ernst et al., 1996; Shaw et al., 1997). 
There is also concern that TCM treatment could indirectly interfere with the effects of 
radio- or chemotherapy, delaying the recovery of patients and putting them at 
unnecessary risk (Brown , 1986; Kaegi , 1998). There is an urgent need that the health 
care practitioners understand the CAM products their patients are using and are familiar 
with the information about the safety and efficacy of these herbal products (Smith et al., 
1999). 
Western medicine is based on an understanding of anatomical structures or organs and 
the cause of disease is viewed as the pathological function of these organs – a diseased 
structure causes dysfunction of the body. In contrast, TCM is based on the “system 
theory” and the human body is viewed as a part of a complex structure of organs – liver, 
heart, spleen, lung and kidney (these do not correspond to the exact anatomical 
structures known in Western medicine). This system undergoes spatial, functional and 
temporal changes and allows open exchange of substance and energy with the 
environment and interaction/ interrelation between the organs/ compartments in the 
body.  The main substance of energy transfer is qi which can’t be seen but can be 
detected by modern technology (Seto et al., 1992). The imbalance in the fluctuation of 
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internal and external energy and a weakened self-regulatory power can cause disease. 
This is a chain reaction of chemical, physiological and biological changes. In TCM, the 
etiology of a disease is attributed to the malfunction of the system which causes a 
change in the organs – the emphasis is based on the function/ dysfunction of an organ 
which triggers pathological structural changes in the organ. The main principle of TCM 
treatment is to cure this deviation by eliminating the pathological factors and by 
strengthening the self healing (Cheng, 2005). 
Appropriate application of dosages of Chinese herbs based on differentiation of 
symptoms and signs is important in order to achieve better therapeutic results with less 
adverse effects. The diagnosis is not disease- but patient-specific. The TCM physicians 
place great emphasis on the severity of disease, the form/ formula/ dosage of the herbs, 
gender and age of the patients. Different patients may have different reactions to the 
same herbs and the same formulae with different dosage/ amounts/ proportions of 
Chinese herbs may have different functions and indications, thus making the treatment 
individually tailored (Deng, 2002). This also makes TCM-related clinical trial designs 
very challenging. 
 
1.2  Herbs used in TCM for cancer treatment 
In TCM, cancer is viewed as the result of imbalance of the whole body-mind network 
by taking into account the human body as whole. The tumor is due to stagnation or 
accumulation of pathological elements (qi, blood, phlegm or body fluids). This 
functional disorder leads to structural changes (tumor growth) when the body loses its 
capacity for recovery. The aim of herbal treatment is to strengthen and restore the yin 
and yang balance, the Five Organs System, the external and internal factors in order to 
cure the cancer.  In conventional medicine, the therapeutic aim is to destroy the cancer 
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cells and prevent their spread by applying chemo-, radio, hormonal and surgical 
treatments.  
There is emerging evidence that TCM can play an important role in the supportive 
treatment of cancer patients. Though the way cancer and its treatment is viewed in 
Western (disease-specific) and Chinese medicine (patient-specific) is very different, the 
holistic approach of TCM could possibly be integrated into conventional Western 
medicine to palliate the side-effects of  the latter (Wong et al., 2001). 
Plants have been used as medicinal agents for centuries, and they continue to play an 
important role in primary health care. More than 50% of all drugs in clinical use are 
derivatives of natural products and 12 of the world’s 25 best–selling pharmaceuticals 
originate from plants (Baker et al., 1995). 
Natural product extracts like Aloe vera (to treat burns and skin abrasions), Echinacea 
(to boost the immune system and fight common colds), Allium sativum (to lower high 
cholesterol levels), Ginger (for immunostimulation and inhibition of cancer metastasis), 
Ginkgo biloba (antioxidant, for improving microcirculation in the brain, reducing 
tendency for blood clot formation), Glucosamine (to rebuild and maintain worn 
cartilage), Artemisia annua (for treating fever and drug resistant malaria), Green tea 
(antioxidant), Lingzhi (to stimulate the immune system, anticancer properties), Royal 
jelly (high vitamin, amino acid and mineral content),  Vitex Agnus castus (to balance 
estrogen-progesterone level), Lavandula augustifolia (anti-inflammatory), Pinus 
sylvestris (adrenal cortex stimulant) and Tanacetum annum (anti-histamine) are popular 
health supplements (Dewick, 1999; Effert, 2005; Schnaubelt, 2005). 
The most well-known anti-cancer drugs derived from natural products are the Vinca 
alkaloids (Vinscristine, Vinblastin, Vindesin), Epipodophyllotoxins (Etoposide), 
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Taxanes (Paclitaxel, Docelatel), Camptothecins (Topotecan, Irinotectan), and the 
antibiotics (Doxorubicin, Mitomycin, Bleomycin) [Rang et al., 2003]. 
According to TCM, herbal treatment can eliminate the disease indirectly by boosting 
the host immune system (immunostimulation) and directly by eliminating the disease 
(cytotoxicity). The herbs prescribed for tumors are usually (a) tonifying herbs which act 
on multiple organ systems and stimulate the immune system and (b) tumor-dispersing  
herbs which eliminate the pathological external factors (i.e. stress, unhealthy diet and 
lifestyle). 
The guiding principles in TCM treatment of tumors are: “supplementing qi and 
nourishing blood” (in biomedical terms: to stimulate the bone marrow and increase the 
white blood cell count); “dispersing the lucid and sending down the turbid” (to protect 
renal function, decrease serum urea nitrogen and creatinine level); relieving abdominal 
distention (due to accumulation of gas from long-term bed rest), “ regulating the flow of 
qi”, (removing blood stasis to alleviate the pain and reduce fever due to 
infections)[Zhou et al., 2001].  
The specific aim of herbal TCM is to slow disease progression by modulating the 
neuro-endocrine and immune systems, to inhibit the tumor growth and to improve the 
quality of life of the patients. Different herbs with different disease fighting pattern are 
used simultaneously, assuming that groups of chemicals in these herbs produce a cluster 
of actions on various cells, cellular organs and multiple receptors, thus achieving a more 
efficient cure. In TCM, these herbs are used for their organ system properties (the way 
they can rectify the functional and structural deviation in the body) and not for their 
chemical properties. In Western medicine usually a single chemical compound is used 
to act on a single cell type and receptor, however (especially with chemotherapeutic 
drugs) the physicians tend to use multi-drug treatments to palliate the side-effects of the 
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anticancer drugs. TCM takes into consideration the property of a whole herb thus using 
multiple chemical compounds which work synergistically on multiple systems, 
receptors and enzymes (Swee, 2005). For example, a mixture of TCM herbs for breast 
cancer patients would contain herbs which aim not only to shrink the tumor itself but 
also palliate insomnia and anxiety, enhance appetite and boost the immune system, thus 
having an integrated effect on the different symptoms of a breast cancer patient. 
Chinese herbs have been reported to have the effect of blocking precancerous lesions by 
removing carcinogenic factors and by chemoprophylaxis, as well as slow the 
development of tumors by inhibiting cancer cell infiltration into the surrounding tissue 
and thus reduce metastasis (Wu et al., 2001; Niu et al., 2003). 
Treatment with CAM interventions could also reduce the oxidative stress in cancer cells 
(Nelson et al., 2001). 
At the cellular level, the tumor-reversing effects of Chinese herbs could occur either by 
inducing early stage apoptosis of tumor cells or by repressing proliferation and causing 
arrest of cancer cells at the G0/G1 stage (Yano et al., 1994). 
The use of TCM is very much embedded in Chinese culture both in Singapore and 
Hong Kong. As many breast cancer patients believe that diet is responsible for their 
cancer, food, diet and herbs should also play an important role in the management of 
their illness (Simpson, 2003). 
In Singapore, herbal TCM is the most popular type of alternative medicine. Most of the 
patients seek TCM treatment because they believe it has less side-effects and toxicity, 
and can enhance their immune system.  
In the breast cancer patients we studied, herbal TCM was used to complement 
conventional treatment (surgery, radio-, chemo- and hormonal therapy). We sought a 
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scientific evaluation of the immunomodulatory effects of some Chinese herbs used 
widely in breast cancer patients at two TCM Clinics that we surveyed. 
While the patients in this study had the same diagnosis (breast cancer), their diagnosis 
according to TCM principles could be very different and variable at each visit 
(stagnation of qi, blood, phlegm, body fluids; dampness type; heat type etc).   
Each TCM practitioner has his/her preference for the type of herb(s) to prescribe, 
whether raw herbs or processed mixtures of herbs. It is also very challenging for the 
practitioner to standardize the prescriptions since it is given individually for every 
patient depending on his/her medical condition.  
The most commonly prescribed TCM herbs for our six breast cancer patients were: 
herbs to tonify the qi - Codonopsis pilosula, Astragalus membranaceus, Atractylodes 
macrocephala, Ziziphus jujuba (red date), Lycium barbarum  (wolfberry fruit); herb to 
invigorate the blood - Curcuma aromatica; herb to relieve food stagnation – Crataegus 
pinnatifida; herbs to drain dampness - Poria cocos, Coix lacryma Jobi (Job’s tears 
seed); herbs to clear heat and relieve toxicity- Scutellaria barbata, Solanum nigrum  
(Reid, 1993; Keys, 1997).   
Herbs that tonify qi decrease lethargy, fatigue, lack of appetite, abdominal pain, 
diarrhea, dyspnoea, edema and stimulate the body and the sympathetic nervous system. 
Herbs that invigorate the blood alleviate pain, while those which relieve food stagnation 
stimulate digestion and increase gastrointestinal secretion.  Herbs which drain dampness 
are diuretics and have tranquilizing effect, while those which clear heat and relieve 
toxicity have anti-inflammatory, anti-infectious and diuretic effects. The combination of 
these herbs might explain their efficacy in improving the quality-of-life (QOL) in 
cancer patients (Read, 1977). 
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The effects of the prescription herbs initially were evaluated through a QOL analysis 
using the European Organization for Research and Treatment of Cancer (EORTC) QOL 
questionnaire (QLQ-C30 version 3.0) and the supplementary breast cancer module 
(QLQ-BR23). We compared the herbal prescriptions of the patients who had better 
scores on the symptoms scale (i.e. less fatigue, pain, dyspnoea, insomnia and appetite 
loss) and selected the 6 most frequently used herbs: Astragalus membranaceus (AM), 
Curcuma aromatica (CA), Solanum nigrum (SN), Scutellaria barbata (SB) for studies 
on their immunomodulatory and cytotoxic effect. Crataegus pinnatifida (CP) and 
Ziziphus jujube (ZJ) were well documented in the literature for their appetite enhancer 
and anxiolytic effect respectively, thus in our research project we did not conduct 



















Astragalus membranaceus L. (AM) (Huang Qi, Mongolian Milk Vetch,) is native to 
China, Korea and Japan. It contains glycosides (astragalosides I, II, III, IV, V, VI, VII) 
[Hirotani et al., 1994], isoflavonoids (Wu et al., 2005; Zhang et al., 2005), 
polysaccharides (astroglucan A, B and C), more than forty types of saponins (Yang et 
al., 2005), vitamin A, betaine, beta-sitosterol (Kim et al.2003), hexuroic acid, 
rumatakenin and sugars (He et al., 1990). In TCM, AM has been used to correct the 
deficiency of qi, repair and tonify emptiness. It is used as a diuretic, a cardiotonic and to 
relief fatigue hypotension (Wu et al., 2000; Fetrow et al., 2001).  
In Western medicine, it has been reported that the saponins and polysaccharide 
compounds found in the Astragalus root support and stimulate the cellular immune 
system, strengthen the natural defence mechanism by enhancing antibody production 
through increased T helper cell activity (Yoshida et al., 1997; Shan et al., 1999; Lee et 
al., 2005). It was reported that Astragaloside VII is a potent IL-2 inducer thus being a 
strong immunostimulator (Yesilada et al., 2005). It was shown that the extract of AM 
stem and leaves could promote lymphocyte proliferation, elevate T cell count and 
enhance IL-2-induced LAK activity thus having antineoplastic effect (Wang et al., 
1992; Jiao et al., 1999). It was also reported that AM is effective in treating Coxsackie 
B virus induced myocardial muscle injury (Yang et al., 1990; Yuan et al., 1990). Used 
in combination with other herbs, it could reduce serum virus count in some AIDS 
patients (Chang et al., 1988; Yao et al., 1992). The saponins have been found to have 
anti-diabetic (Li et al., 2004), neuro-protective (Luo et al., 2004), cardio-protective 
(Zhang et al., 2005), anti-inflammatory (Zhang et al., 2003), diuretic and 




















Curcuma aromatica L. (CA) (Yu Qin, Wild Turmeric) is a member of the 
Zingiberaceae family, like ginger and cardamon. It grows in tropical countries like 
Samoa, Tonga, Jamaica, Peru, Brazil, Jordan, India, Indonesia and South-China 
(Govindarajan, 1980). It contains, among others, curcumin, curcumenol, tumerone, 
atlantone, diaryl heptanoids, zingiberone, sugars, resins, proteins, different vitamins and 
minerals (Kojima et al., 1998; Navarro et al., 2002; Xia et al., 2005; Yang et al., 2005). 
It is known to be an energy regulator and is used in energy stagnant illnesses. CA is a 
mass-reducing herb and has been used to remove the stagnation of qi, reduce 
inflammation, chest pain and colic (Bensky et al., 1986; Reid,1993; Dewick, 1997;  
Dharmananda 1997; Fetrow et al., 2001; Park et al., 2004;  Jayaprakasha et al., 2005). 
In Western medicine, it has been reported to enhance fibrinolysis (Srivastava et al., 
1989), to treat atherosclerosis (Ashraf et al., 2005), pain (Navarro et al., 2002), 
cholelithiasis (Niederau et al., 1999), irritable bowel syndrome (Brinkhaus et al., 2005), 
bacterial and fungal infections ( Grosvernor et al., 1995). It has been shown to be useful 
in the prevention and treatment of breast cancer (Inano et al., 2000), colorectal cancer 
(Goel et al., 2001), skin (Huang et al., 1997) and liver cancer (Cheng et al., 2001).  
Curcumin, a potent bioactive compound in CA, was shown to have anti-HIV activity ( 
Mazumder et al., 1995) to inhibit carcinogenesis by being a strong antioxidant ( Selvam 
et al., 1995; Abas et al., 2006) and to induce apoptosis in cancer cells without cytotoxic 
effect on healthy cells (Duvoix et al., 2005). Curcuminoids are effective by inhibiting 
leukotriene biosynthesis, reducing prostaglandin formation thus having a potential anti-





Picture 3. Reconstruction of Solanum nigrum (authenticated Dr. Ruth Kiew and 






Solanum nigrum L (SN) (Black nightshade) is a common herb that grows wildly and 
can be found worldwide. SN has been used in many different countries (China, India, 
Israel, Turkey, Madagascar, Lesotho, Tanzania, Mexico, Brazil, Hawaii, Cook Islands) 
as traditional folk medicine and for its various biological activities (Dafni et al., 1994; 
Ankli et al., 2002). It belongs to the Solanacae family and contains, depending on the 
parts of the plant (stem, leaves, fruit), steroidal glycosides (α and β2-solamargine, 
solamargine, degalactotigonin), steroidal alkaloids (solasodine, solanidine), flavonols, 
sitosterol, stigmasterol (Dewick, 1997; Keys, 1997; Hu et al., 1999; Fetrow et al., 2001; 
Zhao, 2004). There is a lot of debate over whether or not the leaves or fruit of SN are 
poisonous and carcinogenic. However, in some countries it is consumed as a vegetable 
(Purchase et al., 1975; Blankmeyer et al., 1998, Sammon, 1992). It was reported that 
the unripe fruit contains the highest concentration of solasodine which is a cytotoxic 
substance for cancer cells. It is active against anaphylactic and hypoglycaemic shocks, 
and shocks resulting from burns (Eltayeb et al., 1997; Latoxan, 2005). It was shown 
that SN and some of its compounds has antitumor (Chiang et al., 1991; Yen et al., 
2001; Son et al., 2003; Cai et al., 2004), antifungal (Locher et al., 1995), cholesterol-
lowering (Lee et al., 2005), antipyretic and diuretic (Bensky et al., 1986) effects. It is 
also used to treat inflammation, edema, mastitis (Sultana et al., 1995), liver complaints 
(Goodman et al., 1988), neurological conditions ( Perez et al., 1998) and for 
cytoprotection in drug induced kidney damage (Kumar et al., 2001). The steroidal 
glycosides from Solanacae species can be used to treat herpes simplex and skin cancer 
(Cham et al., 1987; Bensky et al., 1986; Ikeda et al., 2000). It has also been reported 
that solamargine together with cisplatin was effective in treating lung and liver cancer 
(Kuo et al., 2001).  
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Scutellaria barbata (SB) (Skullcap) contains flavonoids (scutallarein, scutellarin), 
sesquiterpenes, wogonin, lignin, resin etc. It is known to have anti-inflammatory, 
anticonvulsant, sedative and cardioprotective action (Fetrow et al., 2001).  It was 
reported that SB induces apoptosis in human leukemia cells (Cha et al., 2004) and has 
anti-cancer/ cytotoxic activity in lung and ovarian cancer (Yin et al., 2004; Powell et 
al., 2003). 
Ziziphus jujuba (ZJ) (Spina Date Seed) is rich in phytoestrogens, which are known to 
have anxiolytic activity and increase appetite (Lund et al., 2001). It is used in TCM 
treatment of insomnia, neurasthenia and palpitation (Zhao, 2004). 
Crataegus pinnatifida (CP) (Hawtorn) has high content of bioflavonoids and was 
reported to have antioxidant and cardioprotective properties (Fetrow et al., 2001).  It 
was published that the corosolic acid isolated from the fruit of CP is a protein kinase C 
inhibitor and has cytotoxic effect on leukemia cells (Ahn et al., 1998). In TCM it is 
used for dyspepsia, diarrhea, abdominal pain, hypertension and hyperlipidemia (Zhao, 
2004). 
Herbal TCM (due to the many different compounds used together) usually exhibit 
synergistic antitumor activity. One of the mechanisms of TCM in cancer treatment is 
immune system modulation by stimulatory, suppressive or regulatory activity or a 
combination of these effects (Patwardhan et al., 2005). Some of the most common 
TCM- stimulated cytokines are Tumor Necrosis Factor- α (TNF-α), Interleukin-2 (IL-
2), and Interleukin-6 (IL-6). TNF-α (cachectin) is a potent mediator of immune and 
inflammatory responses. It is produced by different activated cells including 
macrophages, granulocytes, T and B lymphocytes, natural killer (NK) cells, fibroblasts, 
and certain tumor cells. TNF can co-stimulate the proliferation of activated T (Thelper) 
and B lymphocytes. TNF-α is selectively cytotoxic for some transformed cell lines and 
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can exert cytotoxic effects against certain solid tumors in lower dose. In vivo, TNF-α 
serves as a primary mediator in protective immune responses against microbial and 
viral pathogens. However, TNF-α in higher dose has also been implicated as an 
inflammatory mediator in a number of pathologic responses including septic shock, 
cachexia and autoimmune diseases (Levinson et al., 1996;  Parslow et al., 2003). IL-6 is 
secreted by Thelper cells and macrophages. It is a multifunctional cytokine which 
regulates immune responses, acute-phase reactions and hematopoiesis. It potentiates the 
effect of IL-1 and TNF-α to further promote T- cell activation. IL-6 also enhances B 
lymphocyte proliferation and differentiation and promotes multi-potent hematopoietic 
cells. It is also an endogenous pyrogen. 
IL-2 (T-cell growth factor, TCGF) is a lymphokine which is produced by antigen-
activated Thelper cells. It is involved in activating all types of acquired immune response: 
Tcytotoxic, Thelper, B-cell growth and differentiation; lymphokine-activated killer (LAK) 
cells and NK cell generation and proliferation. It plays an important immunoregulatory 
role and it is frequently used in cancer therapy. IL-2 also induces other lymphokines 
such as interferon and B-cell growth factor (Gupta et al., 1996; Weir et al., 1996a; Weir 
et al., 1996b; Kresina, 1998). 
 
Another effect of TCM in cancer treatment is cytotoxicity, inducing cell death in solid 
tumors. It was shown that apoptosis (programmed cell death) is the most common type 
of cell death, though it has been reported that cancer cells can undergo autoschizis, a 
novel type of necrosis (Jamison et al., 2002). It has been reported that most cytotoxic 
drugs induce necrosis (of cancer cells in-vitro) at high doses and apoptosis at low doses 
(Schwartzman et al., 1993). 
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Apoptosis is a biochemical and physiological response characterized by distinct 
morphological changes, including pre-lytic DNA fragmentation, cell shrinkage and 
appearance of apoptotic bodies. The underlying mechanism of apoptosis induction 
involves different signal transduction pathways controlled by pro- and anti-apoptotic 
factors (death signals, genetic regulation by transcription factor manipulation, activation 
of effector enzymes) [Renehan et al., 2005].  
The most common apoptosis initiators are: (a) stress (ultraviolet and γ-irradiation, 
hypoxia, growth factor deprivation), cytotoxic T-cells releasing granzyme-B – these 
trigger changes in the nucleus (p53, cyclin D, cyclin E regulation) and/or mitochondria 
(cytochrome c release, (b) cytotoxic drugs and cytokines which bind to the “death 
receptors” (Fas, Apo1, TNFR1, TNRF2). These activate either the effector caspases-3, -
6,-7 or through caspase-9 / poly (ADP)-ribose polymerase (PARP) pathway to cause 
DNA fragmentation in the nucleus (Hengartner, 2000; Desagher et al., 2000; Kaufmann 
et al., 2001; Reed, 2001; Renehan et al., 2005). 
The protein bcl-2 has been shown to play an important role in the apoptotic pathway 
both as pro- and anti-apoptotic regulator (Song et al., 1999). Overproduction of bcl-2 
can result in blockage of apoptosis. The anti-apoptotic property of bcl-2 is possibly 
modulated by the protein Bax, and the Bcl-2: Bax ratio could determine whether a cell 
would undergo apoptosis. Among other chemicals, steroid sex hormones (estrogen) and 
certain natural compounds (flavonoids, terpenoids, alkaloids, polysaccharides) may 
regulate Bax and Bcl-2 levels. Breast epithelium undergoes cyclic apoptosis and 
fluctuation in Bcl-2 protein level during the menstrual cycle and pregnancy. Changes in 
Bcl-2 levels have also been associated with breast cancer (Oltvai et al., 1993; Gee et al., 




1.3  Breast cancer: significance in modern day society 
 
Breast cancer is the most common cancer in Singaporean women and the 3 major ethnic 
groups (Chinese, Malay, Indian) are equally affected. The incidence rate is about 5% 
and more than 1000 new cases are diagnosed yearly (Singapore Cancer Society, 2002), 
while 300 deaths from this cancer occur per year (WHO IARC, 2005). According to the 
World Health Organization (WHO), more than 1.2 million people will be diagnosed 
with breast cancer in 2005 worldwide. While breast cancer is less common at a young 
age (in their thirties), younger women tend to have more aggressive breast cancers than 
older women. The survival rates are lower among younger women (Imaginis, 2005). 
Picture 4. Number of deaths from breast cancer in Singapore among women age 
of 0-85 between years 1963-2002 (WHO IARC, 2005) 
 
 
The risk factors associated with breast cancer are: female, age above 40, family history 
(having a first degree relative with breast cancer), late first pregnancy, early onset of 
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menses, late menopause, diet (high intake of saturated animal fats, decreased fruit and 
vegetable intake), alcohol consumption, weight gain, lack of physical exercise and 
intake of hormones (oral contraceptive pills, hormone replacement therapy) [Ng et al., 
1997].   
In Singapore, the median age at diagnosis of breast cancer is 50 years, approximately 10 
years younger than the Caucasian population (Seow et al., 1996). This could be due to 
the different type of BRCA1 mutations observed in patients of Asian ethnicity, 
especially in those younger than age 36 years (Ho et al., 2000). Breast carcinoma 
presenting at a younger age is usually the invasive type thus requiring very complex 
treatment. 
The conventional breast cancer treatment involves multimodal approaches, such as 
surgery, radio-, chemo- and/or hormonal therapy. In most of the breast cancer cases we 
observed in Singapore, herbal TCM was used to complement conventional treatment.  
It has been established earlier that most of the breast cancer cases are caused by 
hormonal (estrogen, progesterone) imbalance, estrogen being a risk factor in the 
development of this disease. Preventive and therapeutic treatments often target 
estrogen. The most common drugs used are (a) Selective Estrogen Receptor Modulators 
(SERMs): Tamoxifen, Toremifene, Raloxifene; Soy, Flaxseed in CAM (b) Aromatase 
Inhibitors: Anastrozole, Exemestane, Letrozole; Genistein in CAM (c) Hormonal 
agents: Fulvestrant, Goserelin acetate, Megestrol.  
A wide range of conventional chemotherapy is also commonly used: Capecitabe, 
Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Fluorouracil (5-FU), 
Paclitaxel, Vinorelbine (Jellin, 2005). 
Against HER2+ breast cancer the current treatment is Transtuzumab, which is a 
recombinant antibody against the HER2 gene (Piccart-Gebhart et al., 2005). 
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There are also promising results with the angiogenesis inhibiting anti-Vascular 
Endothelial Growth Factor (anti-VEGF) drug , Bevacizumab. 
It has been reported that certain Chinese medicinal plants have estrogenic activities thus 
might have estrogen agonist/antagonist effect. Some of these herbs (Epimedium 
brevicornum, Antrodia camphorat) were tested in-vitro for MCF-7 human cancer cell 
growth inhibition, others are already used for the management of menopausal 
symptoms (Yap et al., 2005; Yang et al., 2005; Zhang et al., 2005). 
There is very little available scientific evidence to validate the efficacy of TCM. 
Singapore, with its dual health-care system, is in a very unique position for clinical and 
laboratory studies to be done to evaluate the effectiveness of the combined use of 
Western and traditional medicine in the treatment of disease states like breast cancer. 
 
1.4  Rationale and purpose of this study 
 
Breast carcinoma is a common cancer in women and is a leading cause of cancer-
related deaths in Singapore and worldwide (Polyak, 2001). Early detection and 
intervention have shown promising results. However, the incidence of this disease is 
constantly growing, causing a greater  impact on health care services to demand new 
cures for this disease. 
It is known that CAM therapies provide psychological benefits (optimism, hope for 
disease control, cure and longer survival) for cancer patients (Di Gianni et al., 2002).  
The objective of our study was to obtain data that may show whether TCM use could 
have beneficial effect on breast cancer patients through improving their quality of life 
(by palliating the side effects of conventional therapy), stimulating their immune system 
and inhibiting tumor growth.  
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The conventional treatment for breast cancer includes surgery, radio-, chemo- and/or 
hormonal therapy. The side-effects of these medical interventions and the stress of 
living with breast cancer can negatively affect the patients’ quality of life. QOL 
research has become an important part of the assessment of cancer treatment in Western 
society. However only two studies (one in Shanghai and the other in Hong Kong) have 
been conducted on Chinese breast cancer patients (Yu et al., 2000; Fung et al., 2001; 
Cui et al., 2004). 
The purpose of our study was to gain scientific evidence that TCM, an ancient type of 
medicine based on empirics and widely used for centuries, could be potentially useful in 
the modern biomedical setting.  
 The results obtained from our study may contribute towards improved treatment of 









































2.1.1. Cell lines and cell cultures 
All cell lines are adherent type and were obtained from American Type Culture 








MCF-7 was derived from pleural effusion of a metastasised adenocarcinoma 
(epithelial) of the human breast. It is estrogen receptor positive and its growth can be 
inhibited by TNF-α. The MCF-7 line retains several characteristics of differentiated 
mammary epithelium including the ability to process estradiol via cytoplasmic 
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estrogen receptors and the capability of forming domes. Doubling time is 29 hours.  If 





Picture 6.MDA-MB-231 cells 
 
 
MDA-MB-231 was derived from metastasised adenocarcinoma (epithelial) of the 
human breast. It expresses epidermal growth factor (EGF) and transforming growth 
factor alpha (TGF- α). Doubling time is around 19 hours. In nude mice, MDA-MB-
231forms poorly differentiated (grade III) adenocarcinoma (ATCC, 2005).  
 
T-47-D 
T-47-D was derived from a patient with infiltrating ductal carcinoma of the breast. It 
expresses androgen, progesterone, glucocorticoid, prolactin, calcitonin and estrogen 





T-47-D was derived from a patient with infiltrating ductal carcinoma of the breast. It 
is estrogen receptor positive. Doubling time is 80 hours. It forms tumors in nude mice 
(ATCC, 2005). 
2.1.2.  Animals 
Inbred male and female BALB/c mice, 5 to 6 weeks old, were obtained from the 
Animal Holding Unit, National University of Singapore. 
Inbred female oophorectomized BALB/c nude mice, 8 to 12 weeks old, were obtained 
from the Animal Research Centre (Canning Vale, Australia). The autosomal recessive 
nude gene in homozygous (nu/nu) mice causes the lack of fur and an abnormal 
thymus. The deficiency in T cell function allows athymic mice to accept and grow 
xenografts as well as allografts of normal and malignant tissues. 
All animal experiments were conducted in accordance with the Animal Welfare Act 
and the Animal Research Extension Act, in facilities approved by the Institutional 
Animal Care and Use Committee. 
 
 
2.1.3. Chemicals and reagents 
BDH Laboratory Supplies (UK) 
Dimethyl Sulphoxide (DMSO) 
 
Hyclone (UK) 
Inactivated fetal bovine serum (FBS) 
 
Merck KgaA (Darmstadt, Germany) 
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Methanol, Ethanol, Hexane, HCl, H2SO4, Dodecyl-sulphate sodium salt (SDS), Ethyl 
acetate, n-butanol 
Innovative Research of America (Sarasota, Florida, USA).  
60 days release 17-β-estradiol (0.72 mg) pellets for nude mice 
 
Sigma-Aldrich (St Louis, MO, USA) 
All other chemicals and reagents used in the present study 
 
2.1.4.  Kits 
BD Biosciences Pharmingen (San Diego, CA, USA) 
Mouse IL-2 BD OptEIATM ELISA Set 
Mouse IL-6 BD OptEIATM ELISA Set 
Mouse TNF-α (Mono/Mono) BD OptEIATM ELISA Set 
 Roche Diagnostics GmbH, Roche Applied Sciences (Penzberg, Germany) 
Cell Death Detection ELISAPLUS  
Cellular DNA Fragmentation ELISA 
 
2.1.5.  Facilities/ Equipment 
-86°C Freezer (Forma Scientific) 
-20°C & 4°C ACMA Refrigerator 
Balance (Precisa 40SM-200A, Switzerland) 
Biological Safety Cabinet (NUAIRE, Plymouth, USA) 
CO2 Incubator (SANYO Electronic Co. Ltd, Japan) 
ELX 800 Microplate Reader (Bio-Tek Instruments Inc., USA) 
Hemocytometer (Fortuna, Germany) 
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HPLC with Phenomenex Synergi 4µ Hydro- RP80A column (Japan) 
Kubota Centrifuge KR400 (Kubota Seisakusho Co. Ltd., Japan) 
Nikon Light Microscope (Nikon Co. Ltd, Japan) 
Beckman pH Meter (Fullerton, CA, USA) 
Tecan Sunrise Microplate Reader (Grödig, Austria) 
UV-1601 Spectrophotometer (Shimadzu, Japan) 
 
 
2.2.  Methods 
2.2.1.       Quality-of-life (QOL) study 
2.2.1.1.  QOL study design 
Our study started in February 2001 at two TCM clinics in Singapore. One clinic is the 
Chung Hwa Free Clinic at Toa Payoh, which is financed by individual donors and 
Buddhist charity organizations. Most of the patients here are from low-income 
households. The other clinic is Teo Acupuncture Hall, a private clinic at Rochor 
Centre, which provides TCM treatment for mainly higher income patients. 
 We chose breast cancer patients for the study since the incidence of this disease is 
increasing worldwide, creating a need for a more satisfactory treatment. Breast cancer 
patients are also ideal candidates for observing the side-effects of chemo- and 
radiotherapy since they have little complications from the tumor itself (compared to 
gastric or pancreatic cancer), thus any change in quality-of-life is most likely to be 
due to the applied treatment itself. 
Thirteen female Chinese patients, age 31 to 53 years, who previously had been 
diagnosed with breast cancer by Western-trained physicians, were selected as the first 
subjects for our study between February 2001 and July 2001. After a month, seven 
 
 30
patients dropped out (mainly because of not returning the questionnaires) and we 
continued to follow up the remaining six patients. Two had been treated with 
radiotherapy, chemotherapy and the hormone receptor  modulator, Tamoxifen; one 
with radiotherapy and Tamoxifen; two with Tamoxifen only; one with herbal TCM 
only. It is noted that five of the six patients recruited had some form of surgery as part 
of their prior conventional medical treatment (Table 1).  
 
Table 1.Conventional treatment of selected patients 
  R: radio-therapy C: chemotherapy T: Tamoxifen TCM: Traditional Chinese Medicine 
Our inclusion criteria were that the patients (a) must have primary, not metastatic, 
breast cancer diagnosed by a biomedical practitioner,  (b) should not have any other 
treated or untreated underlying medical condition, (c) should have had previous or 
current conventional treatment for breast cancer, (d) should comply with TCM and (e) 
should be able to come back for follow-up.  After initial evaluation of the patients’ 
medical history, with regard to the modality of breast cancer treatment including 
previous surgery and the type of herbs used (if any), we explained the nature of our 
non-invasive, purely observational study and obtained the patients’ consent to 




Number of patients 
R, C, T 1 2 
1 R, T 1 
T 2 2 
1 TCM only 1 
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participate in the study by showing them the questionnaire in their preferred language 
(English or Chinese). 
These patients were followed up for their herbal TCM treatment by the same Chinese 
physician, Dr. Teo.  They responded weekly, bi-weekly, monthly or bi-monthly to the 
European Organization for Research and Treatment of Cancer (EORTC) QOL 
questionnaire (QOL-C30 version 3.0) and to the supplementary breast cancer module 
(QOL-BR23) questionnaire (Aaronson et al., 1993) [see Picture 7a, 7b, 8a, 8b and 


























Table 2.Composition of EORTC QLQ-C30  (version 3.0) 
 Scale QLQ-C30 item numbers 
GLOBAL HEALTH STATUS 
Global health status/QoL QL2 29, 30 
FUNCTIONAL SCALES 
Physical functioning PF2 1 to 5 
Role functioning RF2 6, 7 
Emotional functioning EF 21 to 24 
Cognitive functioning CF 20, 25 
Social functioning SF 26, 27 
SYMPTOM SCALES 
Fatigue FA 10, 12, 18 
Nausea and vomiting NV 14, 15 
Pain PA 9, 19 
Dyspnoea DY 8 
Insomnia SL 11 
Appetite loss AP 13 
Constipation CO 16 
Diarrhea DI 17 






The QLQ-C30 questionnaire is designed to measure the physical, psychological and 
social functions of the cancer patients (Kaasa et al., 1995).  It is composed of both 
multi-item and single-item scales.  These include five functional scales (physical, role, 
emotional, social and cognitive function), three symptom scales (fatigue, pain and 
nausea), a global health status scale and six single items (dyspnoea, insomnia, appetite 
loss, diarrhea, constipation and financial difficulties). The physical and role function 
scales have a choice of “yes/no” for response; the two global quality-of-life questions 
have a 7-point linear analogue scale for answers (1 being “very poor”, 7 being 
“excellent”).  All other items have a 1 (”not at all”) to 4 (“very much”) point score on 






















Table 3.Composition of EORTC breast cancer module QLQ-BR23 
 Scale QLQ-BR23 item numbers 
FUNCTIONAL SCALES 
Body image BRBI 9 – 12 
Sexual functioning  BRSEF 14,15 
Sexual enjoyment  BRSEE 16 
Future perspective BRFU 13 
SYMPTOM SCALES   
Systemic therapy side 
effects 
BRST 1 – 4,6,7,8 
Breast symptoms BRBS 20 – 23 
Arm symptoms BRAS 17,18,19 












The breast cancer BR-23 module is meant for use among patients varying in disease 
stage and treatment modality (i.e. surgery, chemotherapy, radiotherapy and hormonal 
treatment) (Sprangers et al., 1996).  The module comprises 23 questions assessing 
disease symptoms, side effects of treatment (surgery, chemotherapy, radiotherapy and 
hormonal treatment), body image, sexual functioning and future perspective. 
Validation studies on the module have been completed in The Netherlands, Spain and 
the United States.  It had been field-tested in a large cross-cultural study involving 12 
countries (EORTC Protocol 15931) (Fayers et al., 1998).  All of the scales and single-
item measures range in scores from 0 to 100.  A high score for an item on the 
functional scale represents a high / healthy level of functioning.  Similarly, a high 
score for the global health status represents a high quality-of-life, but a high score for 
an item on the symptom scale represents a high level of problems. 
Patients on chemo- and radiotherapy answered the questionnaire more frequently 
because it was assumed that their state of well-being would be more likely to fluctuate 
during follow-up.  The questionnaire was self-administered in English or in validated 
Chinese (Mandarin and “Taiwanese Chinese”) translation, depending on the patients’ 
language preference. 
After completing the first QLQ-30 and BR-23 questionnaires, five patients had their 
first herbal TCM treatment, while one patient (who previously had mastectomy) was 
already using TCM at the time of induction into the study.  They subsequently made 
several visits to the clinic, the frequency varying between 3 times per week to once in 
2 months.  Their herbal prescriptions were altered according to their condition at each 
visit, and comprised different air-dried plants which were soaked in water for half-an-
hour and then boiled for two hours. The supernatant decoction was then consumed 
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twice a day, in the morning and in the evening, before or after meals. The patients 
were requested by the TCM practitioner to avoid taking any other type of medicine 
within 1 hour of taking the decoction to minimize the possibility of direct drug 
interactions with TCM.  
Scores were obtained from the completed questionnaires and transformed for 
interpretation and comparison in two ways: (a) baseline (pre-treatment) scores were 
compared with post-TCM treatment scores and (b) baseline scores were compared 
with scores of breast cancer patients published in the manual of EORTC QLQ-30 
Reference Values (Fayers et al., 1999). Our patients were matched by age, gender and 
initial conditions with those from the reference population (Canada, Norway, Sweden, 
Denmark). The Reference Values (general population data based on large random 
samples from the general population in the above-mentioned countries) are based on 
pre-treatment data and give baseline quality-of-life scores for patients according to 
specific cancer sites (breast, prostate, lung, brain etc.) and stage of disease (local/ 
loco-regional/advanced).  
All of our patients were diagnosed with early or advanced but not yet metastasised 
breast cancer and were treated by Western-trained physicians. Comparing our 
patients’ baseline mean scores to the published EORTC reference values, we observed 
a moderate difference in physical and emotional functioning, pain and appetite loss, 
and a little change on the role functioning and dyspnoea scale. This might indicate 
that our six patients in Singapore were different from the reference population in their 
psychological and physiological responses to their cancer, and might have a higher 
threshold of pain perception. 
The patients used herbal TCM as an alternative, complementing the conventional 
therapy. The prescription was adjusted at each visit according to the actual condition 
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at the time of the medical consultation by adding or removing herbs and increasing or 
decreasing the dosage and frequency of the herbal medication. The better quality of 
life could be attributed partially to the patients’ favorable prognosis and the use of 
moderately toxic conventional therapies (Burstein et al., 1999). The higher scores on 
the functional scale and lower scores on the symptoms scale could also indicate that 
herbal TCM can ease some of the symptoms in cancer patients.  
SN 300 mg/kg BWsmall volume tumorsnot efficient  larger, multiple tumorsSN 500 
mg/kg BW could be use as prevention (prophylactic rate75%)not efficient dose of  
tumors 
2.2.1.2. Scoring procedures for the EORTC QLQ-30 and BR-23 
questionnaires 
As a first step, we estimated the average of the items on the functional or symptom 
scale on the QLQ-30 and BR-23 questionnaires. This average is the Raw Score (RS) = 
(I1 + I2 +…+ In) / n (n: number of items). As a next step we applied a linear 
transformation to 0-100 to obtain the Score (S) which was calculated for the 
respective scales as it is shown below (range is the difference between the maximum 
and the minimum possible value of RS): 
Functional scales:   S = {1-(RS-1)/range} x 100 
Symptom scales / items and Global health status/ QOL:   S = {(RS-1)/ range} x 100 
 
2.2.2. Extraction of herbs 
The dried forms of Astragalus membranaceus (AM) root, Curcuma aromatica (CA) 
tuber, Scutellaria barbata (SB) leaves and Solanum nigrum (SN) leaves were 
purchased from Teo Acupuncture & Medical Hall, where the breast cancer patients 
 
 42
obtained their prescription. The herbs were harvested in Southern China (Personal 
communications with Teo Eng Kiat, 2001). 
 
2.2.2.1. Preparation of water and ethanolic extract of Astragalus 
membranaceus, Curcuma aromatica, Scutellaria barbata and Solanum 
nigrum 
The dried herbs were crushed into small pieces with an electronic micronizer. As a 
first step in the fractionation process, we chose the ethanolic extract of these herbs. 
170 g of AM, 180 g of CA, 120g of SB and 130 g of SN were extracted with 80% 
ethanol at room temperature until exhaustion. The preparation was filtered with 
Whatman filter paper GF/A, concentrated under reduced pressure and freeze dried. 
The yield was 19%, 13.3%, 9.2% and 6.5% respectively. 
We also prepared boiled water extracts of 200 g each of AM, CA, SB and SN by 
covering the herbs with sufficient water, bringing to boiling point. After cooling, we 
filtered the extract and proceeded to freeze dry. The yield was less compared to the 
ethanolic extracts, 12.2%, 7.8%, 4.7% and 2.9% respectively. 
 
 
2.2.2.2. Fractionation of the water boiled extract of Astragalus membranaceus 
As a next step we also fractionated the water-boiled extract of AM. The water extract 
of AM was partitioned to obtain ethyl acetate (0.2% yield), butanol (3.3% yield) and 




2.2.2.3. Characterization of the ethanolic and water extract of Solanum 
nigrum  
Following the in-vitro cytotoxic experiments with the ethanolic extract of Solanum 
nigrum, we were interested to further investigate and compare the ethanolic and water 
extract of this herb. The reason being was to see whether there is any major difference 
between the ethanolic extract used in our laboratory testing and the water extract the 
patients were taking.  
We ran both extracts on reversed-phase high performance liquid chromatography 
(HPLC). It was a linear gradient elution at a flow rate of 0.8ml/min on Phenomenex 
Synergi 4µ Hydro- RP80A column (250 x 4.6mm, 4 micron) with acetonitrile and de-
ionized water as mobile phase. Detection was done with a Shimadzu Diode Array 
detector. During the linear gradient elution program, the percentage of acetonitrile in 
mobile phase changed as follows: 0.1 to 5 mins: 0%; 5 to 30 mins from 0% to 100%; 
45 to 50 mins: from 100% to 0%; 50 to 60mins: 0%.  
The peaks obtained were detected at four different wavelengths: UV 240, 254, 260 
and 280nm. 
 
2.2.3. Breast cancer cell culture 
 
The human breast cancer cells were cultured for 4-8 passages: MCF-7, T-47D and 
ZR-75 cells were cultured in RPMI-1640, while MDA-MB-231 cells were cultured in 
DMEM medium at 37°C in 5% CO2 humidified incubator. The medium contained 
10% fetal bovine serum, penicillin (100 IU/ml) and streptomycin (100μg/ml). Before 





2.2.4. Cell viability assays by MTT test and trypan blue exclusion  
 
Evaluation of cell activation in the immunomodulatory and cytotoxicity studies was 
carried out using the MTT tetrazolium assay. Briefly, after 48-72 h incubation of 
tissue culture plates at 37°C in 5% humidified CO2  incubator, 10 μl MTT (stock 
solution 5 mg/ml PBS) was added to each well. The plates were again incubated for 4 
h after which 100 μl/well 10% SDS in 0.01N HCl was added to dissolve the formazan 
crystals. After overnight incubation, the plates were read in a microplate reader (ELX 
800, Bio-Tek Instruments, USA) at 570 nm. Wells with medium, MTT and SDS, but 
without cells, were used as blanks (Gerlier et al., 1986; Swamy et al., 2000; Liu, 
2002).  
2.2.5. Lymphocyte-activation assay 
Fresh splenocytes were prepared aseptically into single cell suspension (Nakamura et 
al., 1986; Wu et al., 1990). These were suspended at 1.6 x 106 cells/ml in medium 
containing RPMI 1640 supplemented with 10% heat-inactivated FBS. A total of 90 μl 
of the cells were added to each well of a flat-bottom 96-well plate using a multi-
channel pipette.  Studies were carried out to evaluate the effects of 10.0, 1.0 and 
0.1μg/ml AM and CA extracts on the proliferation of mouse lymphocytes under 
various conditions, in the absence or presence of 10 μl of (a) suboptimal doses of 
ConA (0.3 μg/ml) or LPS (1.0 μg/ml) and (b) optimal doses of ConA (3.0 μg/ml) or 
LPS (6.0 μg/ml).  
The spleen-cell suspensions were incubated for 48-72 h at 37°C in 5% humidified 
CO2 incubator with 10 μl serially diluted extracts, starting with highest concentration 
of 10.0 μg/ml for each extract in quadruplicate wells. Experiments were repeated in 
four replicates for extracts showing stimulation of the splenocytes. Evaluation of cell 
activation was carried out using the MTT tetrazolium assay. 
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2.2.6. Assay of cytokines IL-2, IL-6 and TNF-α  
6-8 weeks old BALB/c female mice were fed orally for 14 days with AM (50,100, 
200 mg/BW kg).  Blood samples were collected by cardiac puncture and the serum 
was analyzed for IL-2, IL-6 and TNF-α. 
To measure cytokine production we used an assay that employs the quantitative 
'sandwich' enzyme immunoassay technique. The sample was blood serum, obtained 
by cardiac puncture from BALB/c 8 weeks old female mice. 
Nunc Maxisorb 96 MTP was coated with 100 μl/well diluted capture antibody and 
incubated overnight at 4°C. After washing 3 times, the wells were blocked with 200 
μl/well assay diluent. Following an hour incubation at room temperature (RT), the 
plates were washed 3 times. 100 μl/well standard solution, serial dilution and serum 
sample was added to the plates. After 2 hours of incubation at RT, the plates were 
washed 5 times.  
For the TNF-α and IL-6 assays 100 μl/well detection antibody plus Avidin-HRP was 
added. After 1 hour of incubation at RT, the wells were washed 7 times and 100 μl 
substrate solution was added to each well. Following 30 minute incubation at RT in 
the dark, 50 μl/well stop solution was added.  
For the IL-2 assay 100 μl/well detection antibody was added first, then after 5 washes 
100 μl/well Avidin-HRP was added. 
As a last step for all 3 assays, the MTP was read @ 450 nm within 30 minutes. Color 
development was in proportion to the amount of cytokine bound in the initial step. By 
comparing the optical density of the samples to the standard/ serial dilution curve, the 





2.2.7. In-vitro cytotoxicity assay 
Sub-cultured, trypsinized human breast cancer cells MCF-7, T-47D, ZR-75 and 
MDA-MB-231 were centrifuged @ 900 rpm for 5 minutes. After discarding the 
supernatant, the cells were re-suspended in medium. The cell suspension was diluted 
to 5x105 cell/ml concentration using trypan blue to determine total cell counts and 
viable cell number (non-viable cells dye blue). 95 μl of cell suspension was added to 
each well. After 2 hour incubation, 5 μl of serially diluted AM, CA, SB and SN 
extracts were added to the respective wells. 5 μl 6-MP was the positive control and 
10% DMSO in sterile water was the negative control. After a 48 hour incubation at 
37°C in 5% humidified CO2 incubator, MTT-tetrazolium assay (see 2.2.4.) was 
applied and the absorbance was read @ 570 nm using microplate reader. The 
inhibition rate and ED50 were calculated as follows: 
 
inhibition rate%=  (T cells with extract - cells with medium)      X 100%  
  (T cells with solvent - T cells with medium) 
 
T: optical density of cells under different treatments (with or without extract) 
ED50 is the calculated effective dose which inhibits growth by 50%  
 
2.2.8. In-vitro analysis to determine the type of cell death 
2.2.8.1. DNA fragmentation ELISA assay (Fig.1)  
After the promising in-vitro cytotoxic experiments we were focusing on SN as a 
potential cytotoxic agent which could be used in breast cancer treatment.  
Exponentially growing human breast cancer cells MCF-7 were diluted with culture 
medium to obtain a cell concentration of 1x105 cells/ml. 100 µl of diluted cells (104 
cells) were added to each microplate well. The cells were incubated with SN extract 
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for 4, 8, 12 and 24 hours at 37° C and 5% CO2. Negative control was 10% DMSO in 
sterile water, positive control was DNA-histone-complex, background control was the 
incubation buffer. After the respective incubation periods, the MTPs were centrifuged 
(200 x g for 10 minutes). The supernatant (S1: contained necrotic DNA that leaked 
through the membrane during the incubation) was used to analyze necrosis, the pellet 
was lysed and centrifuged again. The supernatant (S2: the cytoplasmic fraction) was 
used to detect apoptosis. 20 µl of S1 and S2 were transferred into the streptavidin-
coated MTP and continued with ELISA: 80 µl of the Immunoreagent was added to 
each well and incubated on a microplate shaker (300 rpm for 2 hours at 15–25°C). 
After rinsing MTP 3 times, 100 µl  ABTS solution/well was added. After incubation on 
a plate shaker (250 rpm 10-20 min) the samples were measured @ 405 nm against 
ABTS solution as a blank (reference wavelength @ 490 nm). 
Figure 1. Cell death detection ELISAPLUS (Roche, 2005a)  




The values were averaged and the background value (Incubation buffer + ABTS 
solution) was substracted. The specific enrichment of mono- and oligonucleosomes 
released into the cytoplasm was calculated from these values using the following 
formula: 
                              mU of the sample (dying/ dead cells) 
enrichment factor   =  ----------------------------------------------------------- 
mU of the corresponding negative control (cells without SN treatment) 
 
mU = absorbance [10-3] 
 
 
2.2.8.2. Cellular DNA fragmentation assay (Fig.2) 
 
Sub-cultured MDA-MB-231 breast cancer cells (2-4 x 105) in tissue culture flask were 
pre-labeled with the non-radioactive thymidine analogue BrdU overnight at 37°C in 
5% humidified CO2 incubator. The labeled cells were further incubated in the 
presence of SN extract at different concentrations (10-400 μg/ml) for 2, 4 and 6 hours. 
The negative control was 10% DMSO in sterile water, the positive control was 
camptothecin (0.1 μg/ml).    
At the end of each incubation period, the cells were centrifuged @ 900 rpm for 5 
minutes. The supernatant (S1) was analyzed for necrosis and the cellular lysate was 






               Figure 2. Cellular DNA fragmentaion ELISA (Roche, 2005b) 
 
              
 
The wells of a MTP were coated with anti-DNA antibody, S1 and S2 samples were 
added into duplicate wells and incubated for 90 minutes. After washing the MTP, the 
samples (some of them containing immunocomplexed BrdU-labeled DNA-fragments) 
were denaturized by microwave irradiation (500W for 5 minutes). Anti-BrdU 
antibody peroxidase conjugate (Anti-BrdU-POD) was added to form an 
immunocomplex with the BrdU-labeled DNA. Following 90 minutes of incubation, 
peroxidase substrate (TMB) was added to the wells and after  10-30 minutes of 
incubation the absorbance was measured @ 405nm wavelength using an ELISA plate 
reader.  
 
2.2.9. Animal handling  
2.2.9.1. Housing and maintenance 
The animals (Swiss albino, BALB/c, BALB/c nude mice) were kept in filter-covered 
plastic cages, housed in a temperature-controlled (28°C) room with a diurnal 12 hours 
light cycle, and provided with tap water and standard rodent diet ad libitum. The nude 




2.2.9.2. Mice gavage 
BALB/c mice were restrained by grasping the nape, and a gavage tube was then 
inserted into the oral cavity of the mouse, moved downwards into the esophagus and 1 
ml herbal extract was administered. 
 
2.2.9.3. Blood collection by intracardiac puncture 
BALB/c mice were euthanized by cervical dislocation and a hypodermic needle was 
inserted on the left lateral side of the sternum. Blood was aspirated and centrifuged to 
separate plasma and serum. 
 
2.2.9.4. Intraperitoneal (i.p.) injection 
After restraining the mouse, the abdominal area was wiped with alcohol swab and a 
hypodermic needle was inserted into the lower left/ right quadrant of abdomen. To 
confirm proper placement of the needle, the syringe was aspirated and the herbal 
extract (average 0.2 ml) was then administered in a steady, fluid motion. 
 
2.2.9.5. Acute toxicity test 
For the investigation of the acute toxicity of SN and to estimate the LD50, we used 
both normal (SN water extract) and nude (SN ethanolic extract) BALB/c mice. We 
tested ethanolic extract in nude mice since the in-vitro experiments demonstrated 
stronger cytotoxic effect than the water extract and our future in-vivo experiments 
involved nude mice. 
The doses were 10, 100, 1000, 2000, 5000 mg/BW intraperitonially (i.p.) in normal 
and 1500, 1750, 1875, 2000, 2250, 2500 mg/BW i.p. in nude mice. Both experiments 
included  control groups, each treatment group had 3 animals. Acute poisonous effect, 
 
 51
body weight and behavior change was observed daily for a period of 2 weeks. The 
tests were carried out according to the protocols established by Lorke, 1983. 
 
2.2.10. Breast tumor model in BALB/c nude mice 
2.2.10.1. Tumor xenografts  
In the first phase, 50 mice received subcutaneous intrascapular sustained release 17-β-
estradiol (0.72 mg, released over 60 days) pellet implant (Hawkins et al., 2000). 24 
mice were inoculated with 107 MCF-7 cancer cells into the left and/or right flank 
within 4 weeks of estradiol pellet implant. 
To determinate the size of the subcutaneous tumors, we used the ellipsoid volume 
formula (Osborne et al., 1985; Ware et al., 1985; Riondel et al., 1986) which was 
reported to be the most accurate estimation of actual tumor volume (Tomayko et al., 
1989) and was applied by other laboratories in several breast cancer xenograft models 
(Gottardis et al., 1988; Mimnaugh et al., 1991; Cameron et al., 1997). The tumors 
were measured every four days with calipers in three dimensions (length (A), width 
(B), depth (C) ) in order to calculate tumor volume, V (V=A x B x C x π / 6 mm3). 
2.2.10.2.  In-vivo treatment protocols 
Animals with tumors larger than 8 x π / 6 mm3 (length, width and dimension 
measuring at least 2mm respectively), were selected for treatment with SN extract 
administered via i.p. injection: 300 mg/kg BW in 0.2 ml vehicle for three consecutive 
days per week . The negative control was vehicle (10% DMSO in saline) alone, also 
for three consecutive days each week. The positive control was 5 mg/BW kg 
Doxorubicin in sterile saline, given once weekly. 
In the second phase of the study, 25 mice were implanted with 107  MDA-MB-231 
cancer cell implant into the left and/or right flank. 10 mice started to be treated at the 
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same time of the tumor implant (prophylactic study), 15 mice were selected for 
treatment only after the tumor volume, V, was larger than V=A x B x C x π /6 mm3 
(therapeutic study). The SN extract was administered via i.p. injection: 500 mg/kg 
BW in 0.2 ml vehicle for three consecutive days per week. The negative control was 
vehicle alone, also injected i.p. for three consecutive days each week. The positive 
control was Doxorubicin 5 mg/kg BW in sterile saline, given i.p. once weekly. 
Despite that the patients were consuming the TCM drugs per os, in our cytotoxic 
laboratory experiments all nude mice were given i.p. injection as a more accurate and 
reliable administration route and easily adjustable dose of the SN extract. This is in 
line with the common cytotoxic/ chemotherapeutic drug administration in cancer 
treatment. 
 
2.2.11. Histopathological analysis of tumor tissue section 
The uterine specimens and solid breast tumors were fixed in 10% formalin and 
embedded in paraffin. The sections/ slides were stained with haematoxylin and eosin 
and viewed under light microscope at 40x, 100x or 200x magnification. 
 
2.2.12. Statistical analysis 
The significance of the differences between control and treated values was analyzed 








































3.1 Quality-of-life (QOL) study in breast cancer patients 
3.1.1. Aims and experimental approach 
The objective of the first part of our study was to conduct a QOL analysis among 
breast cancer patients who are using conventional therapy and herbal Traditional 
Chinese Medicine (TCM), in order to identify the medicinal herbs that might have 
immunomodulator and/or anti-tumor effects and could palliate the side effects of 
chemo- and radio-therapy. 
A total of 13 female Chinese patients, age 31 to 53 years, were recruited to respond to 
the EORTC questionnaires QLQ-C30 (version 3.0) and to the supplementary breast 
cancer module (QLQ-BR23).  
The questionnaire was administered in English or in validated Chinese translation. 
During the study, 7 patients dropped out, thus we had only 6 cases to follow up at the 
start (baseline) and 11-13 weeks after the herbal TCM treatment. The scores from the 
questionnaires were transformed, interpreted and compared against breast cancer 












Figure 3. QLQ-30 scores for 2 breast cancer patients receiving radio-, chemo-, 






















































































































For two patients receiving chemo-, radio-, hormonal and herbal TCM therapy (Fig. 3), 
the scores for global health status were 70.3% pre-treatment (70.3% post-treatment).  
The mean scores for each of the functional scales pre- and (post) treatment were: 
physical 85.0% (90.0%), role 75.0% (66.7%), emotional 79.2% (83.3%), cognitive 
83.3% (83.3%), and social 66.7% (83.3%).  
The mean scores for each of the symptom scales were: fatigue 33.3% (27.8%), nausea 
and vomiting 25.0% (16.7%) and pain 8.3% (8.3%), dyspnoea 33.3% (16.7%), 
insomnia 66.7% (16.7%), appetite loss 0% (0%), constipation 0% (16.7%), diarrhea 
16.7% (0%), and financial difficulties 16.7% (33.3%).  
 
On comparing the differences (Δ) between pre- and post-TCM treatment scores, we 
found moderate improvements in social functioning (Δ=16.7%), dyspnoea 
(Δ=16.7%), diarrhea (Δ=16.7%) and clinically very significant decrease of insomnia 
(Δ=50.0%), and little improvement in nausea and vomiting (Δ=8.3) and fatigue 
(Δ=5.5%).  The scores were a little worse for role functioning (Δ=8.3%) and 



















Figure 4. QLQ-30 scores for 1 breast cancer patient receiving radio-, hormonal 




















































































































For one patient receiving radio-, hormonal and herbal TCM therapy (Fig. 4), the mean 
scores for global health status were 33.3% (33.3%).   The mean scores for the functional 
scales were: physical 60.0% (66.7%), role 66.7% (50.0%), emotional 50.0% (50.0%), 
cognitive 50.0% (50.0%) and social 33.3% (66.7%).  The mean scores for the symptom 
scales were: fatigue 55.7% (44.3%), nausea and vomiting 0% (0%) and pain 33.3% 
(33.3%), dyspnoea 0% (0%), insomnia 0% (33.3%), appetite loss 33.3% (33.3%), 
constipation 0% (0%), diarrhea 0% (0%), and financial difficulties 33.3% (33.3%).   
On comparing the differences between the pre- and post-TCM treatment scores, we 
found little improvement in physical functioning (Δ=6.7%), moderately less fatigue 
(Δ=11.3%) and very significant improvement in social functioning (Δ=33.3%).  The 
scores were moderately worse for role functioning (Δ=16.7%) and there was a very 






















Figure 5. QLQ-30 scores for 2 breast cancer patients receiving hormonal and 



































































































































For two patients receiving hormonal and herbal TCM therapy (Fig. 5), the mean scores 
for global health status were 54.2% (62.5%).  The mean scores for the functional scales 
were: physical 90.0% (93.3%), role 100.0% (91.7%), emotional 91.7% (83.3%), 
cognitive 91.7% (83.3%), and social 75.0% (75.0%).   
The mean scores for the symptom scales were: fatigue 22.2% (11.2%), nausea and 
vomiting 0% (0%) and pain 16.7% (16.7%), dyspnoea 0% (16.7%), insomnia 33.3% 
(33.3%), appetite loss 0% (0%), constipation 50.0% (33.3%), diarrhea 0% (0%), and 
financial difficulties 0% (0%).   
On comparing pre- and post-TCM treatment scores, we found insignificant change for 
global health status (Δ=8.3%), moderate improvement for fatigue (Δ=11.0%) and 
constipation (Δ=16.7).  The scores were little worse on role, emotional and cognitive 






























































































































































For 1 patient receiving only herbal TCM therapy (Fig. 6), we used one survey point 
instead of a mean of data. The scores for global health status were 100.0% (post-TCM 
treatment 100.0%).  The scores for the functional scales were: physical 93.3% 
(100.0%), role 100.0% (100.0%), emotional 100.0% (100.0%), cognitive 100.0% 
(100.0%), and social 100.0% (100.0%).   
The scores for the symptom scales were: fatigue 33.3% (11.0%), nausea and vomiting 
0% (0%) and pain 16.7% (0%), dyspnoea 0% (0%), insomnia 33.3% (0%), appetite loss 
0% (0%), constipation 0% (0%), diarrhea 0% (0%), and financial difficulties 0% (0%).   
We found little difference between pre- and post-TCM treatment scores on the physical 
functioning scale (Δ=6.7%), moderately less pain (Δ=16.7%) and clinically very 





























Figure 7. QLQ-30 reference scores compared to the baseline scores of 6 breast 
































































































































We also calculated each patient’s baseline score on each scale of the QLQ-30 
questionnaire, then took the means of the scores of the six patients as our referral 
values, and compared these values with the reference values given in the QLQ-C30 
Reference Value Manual (Fayers et al., 1999).  
The mean score of our six patients for global health status was 63.7% (reference value 
66.3%).   
The mean scores for the functional scales were: physical 83.9% (73.6%), role 86.1% 
(76.6%), emotional 81.9% (67.3%), cognitive 83.3% (83.1%), and social 69.4% 
(77.3%).   
The mean scores for the symptom scales were: fatigue 33.3% (31.4%), nausea and 
vomiting 8.3% (8.8%), pain 16.7% (29.1%), dyspnoea 11.1% (20.1%), insomnia 38.9% 
(31.1%), appetite loss 5.6% (19.9%), constipation 16.7% (13.9%), diarrhea 5.6% 
(7.0%), and financial difficulties 11.1% (13.4%). 
On comparing the six breast cancer patients’ baseline scores from Singapore with the 
scores from the QLQ-C30 Reference Value Manual of breast cancer patients (Fig. 7) 
[Fayers et al., 1999], we found moderately lower scoring on the symptom scales of pain 
and appetite loss and little less dyspnoea among our patients.  On the functional scales, 
the scores for our patients were little better for role function and moderately higher for 
physical and emotional functions; there was no difference between patient populations 








Figure 8. BR-23 scores of breast cancer patients at baseline and after 11-13 


























































































To interpret the scores from the QLQ-BR23 questionnaire, we compared the mean 
QLQ-BR23 scores of our patients before and after herbal TCM treatment (Fig. 8).   The 
scoring for the following items was as follows: body image pre-TCM treatment 84.7% 
(post-TCM treatment 83.3%), sexual functioning 30.6% (43.3%), sexual enjoyment 
66.7% (44.4%), future perspective 27.8% (55.6%).  The scores for the following items 
on the symptom scales were systemic therapy side-effects 23.9% (18.0%), breast 
symptoms 12.5% (18.5%), arm symptoms 12.9% (11.1%) and “upset by hair loss” 
33.3% (16.7%). 
As reference values for the BR-23 module are not available, we compared our 
findings as changes in scores over the 11-13 week period of follow up, using the 
baseline measurement as reference value. We concluded from the findings that after 
herbal TCM treatment, our patients had very much more positive “future 
perspective”. They also had a little better sexual functioning and the systemic therapy 
side effects decreased a little.  On the other hand, their sexual enjoyment decreased 









Figure 9.Single item score distribution of 6 breast cancer patients at baseline and 












































































































































On the single item score distribution (Fig. 9), we can see that the proportion of 
patients complaining of having “quite a bit” or “very much” symptoms decreased 
after herbal TCM treatment: at baseline, 50% of the patients were complaining of 
“quite a bit” of insomnia, which was reduced to 0% after treatment; 20% of the 
patients reported “very much” to having constipation, this changed to 50% of patients 
complaining of “a little bit” of constipation.  But the proportion of patients who had 
“a little bit” of dyspnoea increased from 33% to 50%.   After the treatment, no 
patients complained of having insomnia, appetite loss or diarrhea.  
 
As reference values for the BR-23 module are not available, we compared our findings 
as changes in scores over the 11-13 week period of follow up, using the baseline 
measurement as reference value. We concluded from the findings that after herbal TCM 
treatment, our patients had very much more positive “future perspective”. They also had 
a little better sexual functioning and a little less systemic therapy side effects.  On the 




The responses of the 6 breast cancer patients to herbal TCM were generally favorable. 
The two patients who were using radio, chemo, hormonal (Tamoxifen) and herbal 
TCM therapy had much less dyspnoea, insomnia and diarrhea. The patient who was 
receiving radio-, hormonal therapy and herbal TCM had moderately less fatigue, 
while the two patients who were on herbal TCM treatment at the same time with 
Tamoxifen had much less constipation. When herbal TCM was the only treatment, the 
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patient had a very significant decrease in fatigue, pain and insomnia without 
decreasing other functions or increasing disease symptoms. These might indicate that 
herbal TCM had reduced the side effects of radio-, chemo- and hormonal therapy and 
could be especially useful in palliative cancer treatment.  
Our study has several limitations. Interpreting quality of life data can be approached 
in different ways. According to Fayers (2001), one method is to use the normative 
approach and compare the scores against published data.  In our study, we used the 
QLQ-C30 Reference Value Manual scores (derived from population in Canada, 
Denmark, Norway and Sweden) as our population-based reference values because 
there are no reference values for Asian populations as yet.   
One of the points we need to discuss is how we can compare our findings with 
reference values from a different population having national and cultural differences 
i.e. Singapore’s Chinese population vs Scandinavian population.  A Singapore 
population-based set of national reference values is long overdue.  Such values will be 
of great use to future Asian QOL studies investigating the efficacy of TCM.   
The second issue is how to decide whether a finding is significant.  Clinical 
significance is subjective and statistical significance is not an appropriate method to 
define it, because “for any given change or treatment effect, the P values are affected 
by the sample size” (Fayers, 2001).  Osoba et al., (1998) found that when the scale 
scores changed by 5 to 10 points (on the 0-100 scale), patients described their 
condition as a “little” better or worse. A change of 10 to 20 points was described as a 
“moderate” change, while one greater than 20 was “very much” better or worse.  In 
our study, we found that the 1 patient who was receiving only herbal TCM therapy 
had a “little” (6.7 points) better post-TCM treatment score on physical functioning, 
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moderately less pain (16.7 points) and “very much” less fatigue (22.3 points) and 
insomnia (33.3 points). Other score differences of less than 5 points were thus 
considered to be clinically insignificant.   
The third issue is the possible influence of repeated measurements from the learning 
effect through using the same questionnaire in the same patient over relatively short 
time intervals (1-2 weeks).  This influence could perhaps be minimized by 
administering only 2 questionnaires per patient (baseline and post-treatment).   
The fourth issue is the sample size and selection of the patients. We recruited 13 
patients for this study, but over time 7 dropped out – questionnaires were not returned 
perhaps due to the lack of incentives.  
Last but not least is the issue of the extent of missing values, which were the highest 
(51%) on the sexual functioning scale, thus affecting the validity of the scores for that 
scale. Our impression was that in line with Asian standard pattern of behavior - the 
patients were not willing to answer questions related to their sexual life.  
It needs to be pointed out that the findings from these case studies are subjective; 
evidence from laboratory tests and other investigations (i.e. computer tomography 
scans, X-ray, ultrasound) would be helpful to document the clinical improvement of 







3.2. Extraction and  characteristics of  Solanum nigrum  
3.2.1. Aims and experimental approach 
It has been shown that SN crude extract and some of its individual compounds have 
growth inhibiting effects on different cancer cell lines: colon, nasopharynx, uterine 
and cervix, glioma, melanoma (Chiang et al., 1991), human hepatoma (Kuo et al., 
2001) breast cancer (Son et al., 2003), basal cell and squamous cell carcinoma (Cham 
et al., 1987). Cai et al., in 2004 reported that phenolic compounds found in SN and 
other traditional Chinese medicinal herbs were the dominant antioxidant components  
to which the anti-cancer property of these herbs are attributed to. 
It has also been reported that the bioactive compounds are most likely to be the 
steroidal glycosides β2-solamargine, solamargine and galactotigonin (Hu et al., 1999). 
As the breast cancer patients used the boiled water extract of SN but (as a standard, 
first line laboratory procedure) we used ethanolic extract of SN in our experiments, 
we were interested to know whether there was a major difference between the water 
and ethanolic extracts of SN.  
Our aim was to characterize the SN.  











Figure 10.SN water and ethanolic extract UV spectophotometer scan 





The UV spectrophotometer scan suggested that SN water extract has a high peak at a 
wavelength of 200-400nm (A). The SN ethanolic extract showed 2 peaks, one is 
similar to the water extract, the second one at 650-700nm (B). 
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Figure 11.HPLC chromatogram of SN water extract 
 A B C 
                          
Figure 12.HPLC chromatogram of SN ethanolic extract 
 A B C 
 
The HPLC chromatogram showed three similar peaks (A,B,C ) in both extracts, most 







From the above experiments we can conclude that most of the SN compounds are 
highly polar. Both the water and ethanolic extract had a high peak at 200-500 nm 
where most lipids, steroids (solamargine, solanidine), vitamins and flavoproteins 
show absorbance. The peak at 650-700 nm in the SN ethanolic extract was perhaps 
due to the porphyrins, chlorophylls and derivates ( Teledyne, 2003). 
These experiments revealed that there was no major difference between the boiled 
water and ethanolic extracts of SN. The components present in both extracts perhaps 
were heat resistant steroidal glycosides. 
 
3.3. Results of  in-vitro immunomodulatory studies 
3.3.1. Aims and experimental approach 
Following the EORTC QOL-C30 and QLQ-BR23 analysis, we evaluated the herbal 
prescription of the patients and selected the 2 most frequently used medicinal herbs, 
Astragalus membranaceus (AM) and Curcuma aromatica (CA) for their possible 
immunomodulatory property. 
The immunopotentiating effect of the roots of AM has been associated with its 
polysaccharide fractions (Shao et al., 2004) 
Lymphocyte activation assay was carried out to evaluate the effects of the ethanolic 
extracts of AM and CA on the proliferation of mouse lymphocytes under various 
conditions: in the presence of optimal /suboptimal doses or absence of the mitogens, 
concanavalin A (ConA) and lipopolysaccharide (LPS).  The MTT tetrazolium assay 
was carried out to evaluate lymphocyte activation by measuring lymphocyte activation. 
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We also compared whether the AM or CA ethanolic extract has stronger 
immunomodulatory property. After obtaining the results, we carried out lymphocyte 
proliferation assays comparing ethanolic, aqueous and fractionated aqueous AM 
extracts. This was  
Furthermore, it has been reported in the literature that AM has cytokine production 
modulatory effect (Mao et al., 2004), thus we were interested in the levels of IL-2, IL-6 
and TNF-α cytokines in the mouse serum following AM treatment. 
3.3.2. Results 
3.3.2.1.     Effect of ethanolic extract of Astragalus membranaceus and Curcuma 
aromatica  
Table 4.Effect of different concentrations of 80% ethanol extract of Astragalus 
membranaceus and Curcuma aromatica on BALB/c mice lymphocyte 
proliferation. 
 
 AM CA  
  0.1 1.0 10.0 0.1 1.0 10.0 μ g / m l 
 No mitogen + +    + 
 ConA suboptimal +  +    
 ConA optimal - - - + + + 
 LPS suboptimal       
 LPS optimal       
(+): stimulation, (-): inhibition, empty square: no statistically significant change  
(p value < 0.05).  






As shown in Table 4, in the absence of mitogens, both 0.1 μg/ml and 1.0 μg/ml of 
AM with 10.0 μg/ml of CA stimulated splenocyte proliferation. Neither extract 
caused significant splenocyte proliferation in the presence of B cell mitogen, LPS.  
In the presence of suboptimal dose of ConA, AM at 0.1 μg/ml and 10.0  μg/ml 
significantly potentiated splenocyte activity. AM depressed splenocyte activity in the 
presence of optimal dose of ConA.  
In the presence of optimal dose of ConA, CA at 0.1  μg/ml, 1.0  μg/ml and 10.0 μg/ml 
significantly potentiated splenocyte activity. 
 
3.3.2.2.    Effect of the fractions of Astragalus membranaceus water extract 
Lymphocyte activation assay was carried out according to (Nakamura et al., 1986; 
Wu et al., 1990) to evaluate the effects of 10 μg/ml, 1 μg/ml and 0.1μg/ml ethanolic, 
aqueous and fractionated aqueous AM extract on the proliferation of mouse 
lymphocytes under various conditions:  
[a] in the presence of suboptimal doses of ConA (0.3 μg/ml), LPS (1 μg/ml)  
[b] In the presence of optimal doses of ConA (3 μg/ml), LPS (6 μg/ml)  
[c] without mitogens. 
 
C0.3: conA suboptimal, C3: optimal, LPS1: LPS suboptimal, LPS6 optimal dose 
AM0.1, AM 1, AM10: Astragalus membranaceus 0.1, 1, 10 mg/ml concentration 
 








Figure 12.Immunomodulatory effect of the ethanolic extract of AM on mouse 
lymphocytes 










Figure 14.Immunomodulatory effect of butanolic fraction of aqueous extract of 
AM on mouse splenocytes 
  
Figure 15. Immunomodulatory effect of ethyl acetate fraction of aqueous extract 




Figure 16. Immunomodulatory effect of remaining water fraction of aqueous 





The ethanolic AM extract has shown to be a stronger immunomodulator than the 
boiled aqueous AM extract or any of its fractions (butanol, ethyl acetate or remaining 
water fraction). All boiled water fractions showed a similar trend in the lymphocyte 
activation assay: in the presence of suboptimal dose of ConA the AM extracts 
stimulated the lymphocyte activity, while in the presence of optimal dose of mitogen 
ConA the AM extracts in higher concentration suppressed lymphocyte proliferation. 
However, these changes were not statistically significant. None of the AM extracts 






The results indicate that both AM and CA have immuno-stimulatory effect. 
AM acts best in the presence of suboptimal dose of ConA, while CA caused 
significant splenocyte proliferation in the presence of optimal dose of ConA.  
The responder cells are probably T-cells, as there was increased splenocyte 
proliferation with the T-cell mitogen, ConA. The suppression of splenocytes in the 
presence of optimal doses of ConA with 10.0 and 1.0 μg/ml dose of AM might be due 
to the toxic effect of this extract. It appears that AM has a stronger 
immunomodulating property as it potentiated splenocyte activity at a lower dose than 
CA. 
The ethanolic extract of AM displayed stronger immunomodulatory property then the 
butanolic, ethyl acetate or the remaining water fraction of same. 
The results of these experiments indicate that AM and CA may have a role not only in 
palliative care, but also in enhancing the effects of conventional oncology therapy. 
The stimulating activity on human lymphocytes deserves future investigation. 
3.4. Cytokine studies from mice serum  
3.4.1. Aim and experimental approach 
It was reported earlier that AM is able to produce pro- and anti-inflammatory 
cytokines (Chu et al., 1988a; Chu et al., 1988b): IL-2, TNF-α (Hong et al., 2005),  
6-8 weeks old BALB/c female mice were fed orally daily for 14 days with ethanolic 
extract of AM (50,100, 200 mg/BW kg).  Blood samples were collected by cardiac 




Table 5. Cytokine concentration after AM treatment in BALB/c mice 
 CYTOKINE CONCENTRATION (pg/ml) 
TREATMENT 
DOSE (mg/Bw kg) IL-2 IL-6 TNF-α 
Control 28.4 (+SD0.36) Not enough sample < 3.8 
50 18.8 (SD+0.35) 13.9 (SD+0.02) < 3.8 
100 14.6 (SD+1.1) 24.2 (SD+0.14) < 3.8 
200 19.2 (SD+0.1.1) Not enough sample < 3.8 
three readings for each group, duplicate samples (mean + SD) 
3.4.3. Discussion 
IL-2 level fluctuated between the different AM treatment groups. There was no 
consistent IL-2 inducing activity observed. 
We were able to detect a more then 70% increase in IL-6 serum level in animals 
which where treated with a double dose (50 versa 100 mg/BW kg). The limitation of 
our study was that we had insufficient blood sample from the control and 200 mg/BW 
kg treatment group. 
TNF-α levels were undetectable < 3.8 pg/ml.  The lack of detection might be due to 
the sensitivity of the test  
Our collaborator in USA (Gangemi, 2003) conducted tests with the ethanolic AM 
extract provided by us. Dr. Gangemi tested the inductive effect of AM on human 
lymphocytes in-vitro, measuring the levels of IL-6 and TNF-α cytokines. His findings 
were in line with our results: the ethanolic extract of AM augmented IL-6 production, 
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however seemed to reduce LPS-induced TNF-α levels in a dose dependent manner. 
The underlying mechanism remains to be determined. 
 
3.5. In-vitro cytotoxicity studies 
3.5.1. Aims and experimental approach 
We sought a scientific evaluation of the cytotoxic effects of some Chinese herbs 
widely used in breast cancer patients at 2 TCM Clinics we surveyed. The herbs were 
identified through a quality-of- life (QOL) analysis using the European Organization 
for Research and Treatment of Cancer (EORTC) QOL questionnaire  (QLQ-C30 
version 3.0) and the supplementary breast cancer module (QLQ-BR23). We compared 
the herbal prescription of the patients who had better scores on the symptoms scale 
(i.e. less fatigue, pain, dyspnoea, insomnia and appetite loss) and selected two of the 
most frequently used herbs, Solanum nigrum (SN) and Scutellaria barbata (SB) for 
their possible cytotoxic effects. First we tested them on MCF-7 to confirm the herb 
with the stronger cytotoxic property, then tested its effects on other human breast 




3.5.2.1.   Results of cytotoxicity assays of Scutellaria barbata and Solanum 
nigrum on   MCF-7, MDA-MB-231, T-47D, ZR-75-1 human breast 
cancer cell lines 
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Figure 17.Comparative cytotoxic effect of Solanum nigrum and Scutellaria 

































Solanum nigrum Scutellaria barbata
The results from both SN and SB treatment groups were statistically significant 
(except SB 10 μl/ml and SN 40 μl/ml) in cell growth inhibition (p value < 0.005). SN 





Figure 18.Comparative cytotoxic effect of Solanum nigrum and Scutellaria 




















SN appeared to be a stronger cytotoxic herb then SB. 
The dose-response curve showed that the effect of SN declined after reaching a 
plateau (maximal effective dose) at approximately 30 μg/ml, while the SB curve did 
not plateau. ED50 for SN was 7.76 µg/ml (A) and for SB > 40 μg/ml (B). 












3.5.2.2.      Results of cytotoxicity assays of the ethanol extract of Solanum 
nigrum on MCF-7, MDA-MB-231, T-47D and ZR-75-1 cell lines 
Figure 19.Cytotoxic effect of the ethanol extract of SN on MCF-7, MDA-MB-231, 

















Solanum nigrum on MCF-7 Solanum nigrum on ZR-75-1
Solanum nigrum on MDA-MB-231 Solanum nigrum on T-47D
 
 
The ED50 values for SN treatment were: MCF-7 ED50=7.76 µg/ml < ZR-75-1 
ED50=24.32 µg/ml < MDA-MB-231 ED50=37.08 µg/ml < T-47D ED50=106.26 µg/ml. 
MCF-7 and ZR-75-1 (ERα+, bcl-2+)cell lines were the most sensitive to SN, while 
MDA-MB-231 (ER α-, bcl-2+) was less sensitive, T-47D (ERα+, bcl-2-, prolactin +, 
androgen +) was the least inhibited by SN. Comparing the biochemical markers and 
genes expressed in the different cell lines, bcl-2 and p53 might have a role in the 




3.5.2.3. Results of  DNA fragmentation in MCF-7 cells treated with Solanum 
nigrum 




























































































































Preliminary ELISA DNA fragmentation study suggested that cell death in MCF-7 cell 
line occurred via apoptosis.  Higher dosage (50-400) µg/ml with shorter incubation 
time (4, 8 h) and lower dosage (5-50 µg/ml ) with longer incubation time (12, 24 h) 
were also tested. SN stimulated nucleosome release in a concentration- and time-
dependent manner: (a) after 4 hours of incubation, the necrosis was more dominant, 
(b) after 8 hours of incubation, nucleosome release was present, (c) after 12 hours, the 
intensity of the nucleosome release reached a plateau. 
 
3.5.2.4. Results of DNA fragmentation in MDA-MB-231 cells treated with 
Solanum nigrum 
 
The supernatant (S1, blue) was analyzed for necrosis and the cellular lysate was 
further centrifuged. The supernatant of this cellular lysate (S2, pink) was used for 
apoptosis detection. The logarithmic curve was generated by measuring the 
nucleosome content of lysate S1 and S2 treated with SN after different incubation 
time. 
Figure 24. Cytotoxic effect and cellular DNA fragmentation of the ethanol 


























Figure 25. Cytotoxic effect and cellular DNA fragmentation of the ethanol 
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Figure 26. Cytotoxic effect and cellular DNA fragmentation of the ethanol 
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After 2 hours of incubation of MDA-MB-231 cells with SN, the DNA fragment 
release was more prominent then the high molecular weight DNA release. After 4 




Picture 9. MDA-MB-231 cells incubated with SN extract (100X)   
                   2 hours    4 hours 
Negative control    
 
 
20 µg/ml SN 
 
 
40 µg/ml SN 
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Examination by light microscopy showed increased cellular damage in a time- and 
dose-dependent manner. The characteristics of apoptosis (cell shrinkage, nuclear 
condensation, apoptotic bodies, cell debris) were visible after 2 hours of incubation 
with higher then 80 μg/ml SN dose and after 4 hours of incubation with higher then 
40 μg/ml SN dose. 
3.5.3. Discussion 
DNA fragmentation studies and microscopic examination revealed that incubation 
with SN extract caused apoptotic cell death in both caspase-3 negative MCF-7 and 
caspase-3 positive MDA-MB-231 human breast cancer cells in-vitro. The apoptosis 
occurred within 4 hours, after which secondary necrosis was more prominent. In the 
MCF-7 cells the apoptosis probably occurred in a caspase-3 independent manner.  
The distinctive morphological markers of apoptosis (membrane blebbing, cell 
shrinkage, condensation of chromatin, presence of apoptotic bodies) and the DNA 
fragmentation results were suggesting that the type of cell death could be apoptosis. 
3.6. In-vivo cytotoxicity studies 
3.6.1. Aims and experimental approach 
Our previous in-vitro experiences showed that certain Chinese herbs, including SN, 
can cause cytotoxicity via apoptosis in human breast cancer cells. We found that the 
ethanolic extract of SN appears to have a dose-dependent cytotoxic effect on cancer 
cells in-vitro, with an average ED50 of 7.75 µg/ml for MCF-7 and ED50 of  37.08 
µg/ml for MDA-MB-231.  
Thus we investigated further whether SN crude extract could cause tumor regression 
in athymic mouse model xenografted with hormone-dependent MCF-7 (after priming 
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with estrogen) and hormone independent MDA-MB-231 human breast cancer cells. 
This model is ideal to investigate the actions of antitumor drugs ( Gottardis et al. 
1988; Tomayko et al., 1989; Mimnaugh et al., 1991; Hawkins et al., 2000).  
3.6.2. Results 
3.6.2.1. Acute toxicity test of Solanum nigrum in normal and nude BALB/c 
mice 
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The oral acute toxicity test showed that in Swiss albino mice LD50 was higher then 
5000 mg. There was no significant change in the weight, appearance, grooming and 
activity of the animals after a 2 week period of observation (Fig.29).  
The i.p. administration of SN in nude mice appeared to be more toxic, LD50 being 
around 2000 mg. The animals injected with SN doses higher then 2000 mg showed 
symptoms of tachycardia, psychomotor agitation, paralysis, circulatory and 
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respiratory depression and eventually death within 20 minutes of SN administration. 
Yen et al., 2001, reported that the toxicity could be due to the SN compound 
solasonine. This glycoalkaloid can be transformed into a secondary metabolite in the 
body, entering the blood-brain barrier causing disruption in essential life functions 
(Schwartz et al., 2005).  
Nude mice treated with non-toxic dose had no change in their weight, appearance or 
behavior. 
3.6.2.2. Anti-tumor activity of Solanum nigrum treated MCF-7 tumor 
bearing oophorectomized nude mice 
Prior to SN-treatment, estradiol stimulated the growth of MCF-7 breast tumor 
implants (Pic.10,11,12 ) in BALB/c oophorectomized nude mice. Most of the tumors 
were continuously growing even after estrogen treatment had completed. 
In this study we implanted (estradiol-primed ) 15 mice with MCF-7 cells, chose 20 
weeks as the cut off period to shorten the duration of suffering. 9/15 did not grow 
tumors after 20 weeks and but maintained their body weight (20-26 grams). 6/15 grew 
tumors larger then 8 x π / 6 mm3. 5 of these tumor bearing mice were treated with SN 
from the time when the tumor volume reached 8 x π / 6 mm3. 3 out of these 5 died and 
2 survived. In one of these mice the tumor disappeared, while the other mouse 
maintained its body weight, though the tumor continued to grow. One negative 
control (no SN treatment), died within a week after the tumor volume reached 8 x π / 
6 mm3.  
The total mortality among the MCF-7 implanted mice was 6/15: 2/15 died without 
visible tumor but were cachexic. 3/15 died despite SN 300mg/kg BW treatment, 1/15 




Picture 10. Large solid MCF-7 tumor in estrogen-primed mouse #1 
 








Mice treated with SN did maintain their original weight of 20-26 grams without any 
change in behavior. The tumor-bearing mice without SN treatment became cachexic, 
with bodyweights below 20 grams (Pic.13). 





3.6.2.3.  Estrogen-induced uterine cancer in oophorectomized BALB/c nude 
mice 
We investigated tumor regression in athymic mouse model xenografted with 
hormone-dependent MCF-7 human breast cancer cells after priming with oestrogen. 
As mentioned previously, this model is ideal to investigate the actions of antitumor 
drugs. 
Fifty inbred female oophorectomized BALB/c nude mice (Animal Research Centre, 
Canning Vale, Australia), 8 to 12 weeks old, received implants of 60 days release 17-
β-oestradiol (0.72 mg) pellets (Innovative Research of America, Sarasota, Florida, 
USA). 
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However, incidental findings revealed that 0.012 mg daily (0.72 mg over 60 days) 
estrogen dose induced endometrial carcinoma (Pic.14) with an 11/50 total mortality 
rate (Fig.30). On post mortem examination (Pic.13), the mice had enlarged uteri with 
poorly differentiated cell infiltration. The average enlarged uterine diameter was 10 
mm, compared to a normal of 2-3 mm. 
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Picture 14. Mouse uterine tissue H&E staining 
 
 





3.6.2.3.Anti-tumor activity of Solanum nigrum treated MDA-MB-231 tumor 
bearing oophorectomized nude mice 
 
3.6.2.4.1. Results of therapeutic Solanum nigrum treatment 
In this study we implanted 15 mice with MDA-MB-231 cells. The cut-off for the 
observation period was 8 weeks post-implant since this type of tumor is very aggressive 
and spreads easily. 
6/15 did not grow tumors and they maintained their body weight (20-25 grams). 7/15 
grew tumors, out of which 5 had multiple metastases - 1 to the spine (Pic.16a,b,c,d), 1 
to the orbit (Pic.17a,b,c) These mice received SN treatment – the tumors were growing 
though the body weight did not drop below 20grams. 2 animals with tumors which did 
not received SN treatment became cachexic. 2 mice without measurable tumor but on 
SN treatment also became cachexic. 





























It is shown on both Picture16. and 17. the extensive damage the MDA-MB-231 
implant caused – despite the SN-treatment. Picture 16. shows (a) spinal metastasis, (b) 
a paraffin section of this multi-lobular tumor, (c) H&E staining of a section of the 
above mentioned mass. On Picture 17.  is shown  (a) a large, left orbital, bony  
metastatic mass, (b) the paraffin section of the tumor site, (c) H&E staining of a tumor 
slide under light microscope (40x). 
On both H&E slides is evident the presence of tumor cells with poorly differentiated 
nuclei. Some of the apoptotic bodies are marked with arrows on Picture 16c. 
(a) 
(b) (c) 
Poorly differentiated nuclei ( ) and apoptotic bodies ( ) are marked 
with arrows  on Picture 16(c)and 17(c). 
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3.6.2.4.2. Results of prophylactic Solanum nigrum treatment 
In this study we chose 10 mice, cut-off period at 8 weeks. The grouping was the 
following: positive control Doxorubicin 5 mg/kg (n=3), negative control 10%DMSO 
in saline (n=3) and SN treatment (n=4). The mortality rate in the positive control 
group was 100% probably due to Doxorubicin-induced cardiac toxicity. In the 
negative control group 67% grew tumors, while 33% had no tumor. In the 500 mg/kg 
BW SN treatment group, 25% grew tumor, 75% had no tumor (Fig. 29). SN showed a 
75% prophylactic rate against the growth of the tumor implants. 
 
Figure 29. Prophylactic treatment of Solanum nigrum (ethanolic extract) on 
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3.6.2.5.       Histopathological examination of Solanum nigrum induced apoptosis 
in MDA-MB-231 cells  
Picture 18. SN extract versa saline-treated MDA-MB-231 tumors 
 
  SN-treated        










The H&E stained paraffin MDA-MB-231 tumor sections on the left were treated with 
SN and shows several apoptotic bodies (black arrows) as a marker of apoptotic cell 
death.  
On the right panel we can see mainly necrotic tissue and less apoptotic bodies. 
 
3.6.3. Discussion  
40x40x 
200x 
Our experiment with the MCF-7 induced nude mice showed that the growth of the 
implanted breast cancer cells was highly dependent on estrogen.   
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The results also revealed that the 0.012 mg daily (0.72 mg over 60 days) estrogen 
dose was very high and induced endometrial carcinoma with a 11/50 total mortality 
rate. This seems to suggest that mice models with estrogen-dependent human breast 
cancer need to be hysterectomized in order to avoid the mortality rate from uterine 
cancer. 
We noted that cessation of estrogen at 60 days after pellet implant did not prevent 
MCF-7 cells from growing tumors as occurred even at 10 days after estrogen 
cessation. 
SN treatment caused irreversible tumor regression where the tumor size was relatively 
small. 
In the cases where the mice grew multiple tumors, SN at 300 mg/bw kg  was not 
efficient in inhibiting the tumor growth, but the treated animals retained their original 
body weight despite there being tumor growth, while untreated animals became 
cachexic. 
SN treatment could be used as prevention but the dose is not efficient for the 
treatment of already existing aggressive tumors. 
The acute toxicity test showed that the LD50 for oral SN treatment is higher then 5000 

















CHAPTER FOUR: SUMMARY AND OVERALL 














4.1 Summary of the results 
In the clinical phase of our study we showed that most of our breast cancer patients 
responded favorably to herbal TCM. The two patients who were using radio, chemo, 
hormonal and herbal TCM therapy had much less dyspnoea, insomnia and diarrhea. 
The patient who was receiving radio-, hormonal therapy and herbal TCM had 
moderately less fatigue, while the two patients who were on herbal TCM treatment at 
the same time with Tamoxifen had much less constipation. When herbal TCM was the 
only treatment, the patient had a very significant decrease in fatigue, pain and 
insomnia without decreasing other functions or increasing disease symptoms.  
Our experimental results showed that breast cancer patients benefited from herbal 
TCM use. The possible explanation for this could be that the prescribed herbal 
mixture with its different compounds had different actions: This might indicate that 
herbal TCM had reduced side effects of radio-, chemo- and hormonal therapy and 
could be especially useful in palliative cancer treatment.  
In the laboratory phase of our study we were seeking scientific evidence for the 
therapeutic activity of respective herbs prescribed for breast cancer patients. 
The results indicate that both AM and CA have immuno-stimulatory effect. 
AM acts best in the presence of suboptimal dose of ConA, while CA caused 
significant splenocyte proliferation in the presence of optimal dose of ConA.  
The responder cells are probably T-cells, as there was increased splenocyte 
proliferation with the T-cell mitogen, ConA. The suppression of splenocytes in the 
presence of optimal doses of ConA with 10.0 and 1.0 μg/ml doses of AM might be 
due to the toxic effect of this extract. It appears that AM has a stronger 




The ethanolic extract of AM displayed stronger immunomodulatory property then 
the butanolic, ethyl acetate or the remaining water fraction. 
The results of the immunomodulating experiments suggest that AM and CA may 
have a role not only in palliative care, but also in enhancing the effects of 
conventional oncology therapy.  
The stimulating activity on human lymphocytes deserve future investigation. The 
herbs could have a chemopreventive action by blocking carcinogen activation and 
suppressing malignant cell proliferation (Duvoix et al., 2005). 
MCF-7 and ZR-75-1 cell lines (ERα+, bcl-2+) were the most sensitive to SN, MDA-
MB-231 (ER α-, bcl-2+)was less sensitive, T-47D (ERα+, bcl-2-, prolactin +, 
androgen +) was the least inhibited by SN. Comparing the biochemical markers and 
genes expressed in the different cell lines, bcl-2 and p53 might have a role in the 
mechanism of cytotoxicity of SN. 
The possible chemotherapeutic mechanisms of SN could involve blocking of tumor 
cell cycle progression and/or signal transduction pathways by bonding to TNFR1 or 
TNFR2 receptors, inhibiting the activities of transcription factors (NF-κB), increasing 
the production of nitric oxide thus  triggering apoptosis ( Lee et al., 2003; Son et al., 
2003;  Heo et al., 2004). 
Preliminary ELISA DNA fragmentation study suggested that cell death in MCF-7 cell 
line occurred via apoptosis.  Tested at higher dosages (50-400) µg/ml with shorter 
incubation time (4, 8 h) and lower dosages (5-50 µg/ml ) with longer incubation time 
(12, 24 h), SN stimulated nucleosome release in a concentration- and time-dependent 
manner: a) after 4 hours incubation the necrosis was more dominant, b) after 8 hours 
incubation the nucleosome release was present, c) after 12 hours the intensity of the 
nucleosome release reached a plateau. 
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Further cellular DNA fragmentation studies and microscopic examination revealed 
that incubation with SN extract caused apoptotic cell death in MDA-MB-231 human 
breast cancer cells in-vitro. The apoptosis occurred within 4 hours, after which 
secondary necrosis was more prominent. The distinctive morphological markers of 
apoptosis were evident. 
Our in-vivo experiment with the MCF-7 induced nude mice model showed that the 
growth of the implanted breast cancer cells was highly dependent on estrogen.   
Accidental observations also revealed that the 0.012 mg daily (0.72 mg over 60 days) 
estrogen dose was very high and induced endometrial carcinoma with a 22% total 
mortality rate. This seems to suggest that mice models with estrogen-dependent human 
breast cancer need to be hysterectomized in order to avoid mortality from uterine 
cancer. 
We noted that cessation of estrogen at 60 days after pellet implant did not prevent 
MCF-7 cells from growing into tumors as this occurred even 10 days after estrogen 
cessation. 
SN treatment caused irreversible tumor regression where the tumor size was relatively 
small. 
In the cases where the mice grew multiple tumors, SN at 300 mg/BW kg  was not 
efficient in inhibiting the tumor growth, but the treated animals retained their original 
body weight despite there being tumor growth, while untreated animals became 
cachexic. 
SN treatment could be used in breast cancer prevention. It was however not efficient 
for the treatment of pre-existing aggressive tumors at the doses studied. 
The acute toxicity test showed that the LD50 for oral SN treatment (5000 mg) was 
within relative safety limits. 
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4.2 Overall discussion 
The present work is an attempt to evaluate the efficacy of herbal TCM treatment in 
breast cancer. Scientific evaluation of TCM is extremely challenging. Several 
biomedical experiments have described many possible mechanisms behind the 
success of TCM herbal therapy in cancer: some plants/ components have anti-oxidant, 
anti-angiogenesis, immunostimulator, cytotoxic, cytostatic effects. The molecular, 
genetical mechanisms behind these therapeutic effects are not clear. There is a need 
for scientific proof and clinical validation, including chemical standardization of 
complex herbal formulations, in-vitro and in-vivo biological assays, animal models 
and clinical studies (Yuan et al., 2000). 
Future research and development in herbal TCM should adopt a clinical efficacy-
driven strategy and plan randomized, double-blind placebo trials to evaluate their 
efficacy. However, the obstacle is how to generalize an individualized treatment?  
In our clinical case studies we described 6 patients whose QOL improved and we 
analyzed the prescribed medicinal herbs. This study has demonstrated in the 
laboratory that these herbs are effective individually, but our clinical findings suggests 
that the efficacy of TCM herbs is increased when they are used together, probably due 
to their synergistic interaction. 
As herbal TCM is already in use for over two thousand years, the efficacy driven 
approach should have priority over the current mechanism centered approach (Tang, 
2001). 
TCM has a profound influence on the health care system in Singapore and should be 
























The following results have been demonstrated: 
1. Herbal TCM improved quality of life of the recruited breast cancer patients. 
2. Astragalus membranaceus and Curcuma aromatica exhibited 
immunostimulatory effect in splenocytes. 
3. Solanum nigrum had cytotoxic effects against both MCF-7 and MDA-MB-231 
breast cancer cells in-vitro and in-vivo, and appeared to have a protective 
effect against the growth of metastatic breast cancer. 
 
The findings of this study indicate that: 
1. Astragalus membranaceus and Curcuma aromatica enhanced T lymphocyte 
proliferation and indirectly stimulated cytokine production. 
2. Solanum nigrum induced cytotoxicity (in both estrogen-dependent and -
independent human breast cancer cells) was shown to be by apoptosis. 
5.2 Future studies 
The results of this study show that Solanum nigrum may be useful in the prevention 
and/or treatment of invasive, non-hormone responsive breast cancer.  
It would be worthwhile to identify the bioactive compound(s) of this herb, to further 
investigate the molecular mechanisms of its cytotoxic action and to evaluate the effect 
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